

**IN THE UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF NORTH CAROLINA SOUTHERN DIVISION**

| | | |
|-----------------------------------|---|-----------------|
| RICHARD FREDRICK LANIER, |) | |
| WILLIAM COUNCIL LANIER, |) | |
| AND |) | |
| RICHARD RALPH LANIER, JR. |) | |
| Plaintiffs, |) | |
| |) | |
| vs. |) | Case No: |
| |) | |
| SYNGENTA AG, SYNGENTA CROP |) | |
| PROTECTION AG, SYNGENTA |) | |
| CORPORATION, AND SYNGENTA |) | |
| SEEDS, INC. |) | |

PLAINTIFFS' CLASS ACTION COMPLAINT

COME NOW the Plaintiffs, by the undersigned attorneys, who brings this action individually and on behalf of all others similarly situated against Defendants Syngenta AG, Syngenta Crop Protection AG, Syngenta Corporation, and Syngenta Seeds, Inc., (collectively "Defendants" or "Syngenta") and allege as follows:

NATURE OF THE CASE

1. Richard Fredrick Lanier ("RFL") is an individual resident of North Carolina. William Council Lanier ("WCL") is an individual resident of North Carolina. Richard Ralph Lanier ("RRL") is an individual resident of North Carolina. RFL, WCL and RRL are collectively hereinafter referred to as "Plaintiffs". Plaintiffs are engaged in the business of farming, including ownership

and cultivation of farmland whereby corn is planted, grown, harvested and ultimately sold. The Defendants are corporations actively doing business in the state of North Carolina and within this District, thus are subject to personal jurisdiction. Venue lies in this district because a substantial part of the farmland and the associated corn farming operations of the Plaintiffs and those similarly situated forming the subject and the basis of this action are situated in this District and a substantial part of the events or omissions giving rise to this action occurred in this District. Jurisdiction of this Court is proper because the amount in controversy far exceeds the minimum jurisdictional requirements of this Court.

2. Syngenta's conduct and fault is more fully described in exacting detail below, and as a consequence of the Defendants' actions Plaintiffs and those similarly situated have suffered substantial damages, and their ability to profitably grow, cultivate, harvest and market corn is at great risk. By way of background, beginning in 2009, Syngenta released, prematurely, a genetically modified corn trait, MIR162, under the trade name Agrisure VIPTERA™ ("VIPTERA") into the U.S. market. Syngenta's actions thereafter and as more specifically described herein caused the contamination of the entire U.S. corn supply with a genetic trait called MIR162. MIR162 is prohibited from sale in countries such as China where it has not been approved for either purchase or consumption.

3. A substantial amount of the total U.S. corn crop, specifically

including North Carolina's corn production, is exported. The U.S. exports of corn amount to billions of dollars annually. Further, the U.S. corn marketing system is commodity-based, meaning the corn grown by farmers such as the Plaintiffs and those similarly situated to the Plaintiffs in North Carolina and throughout the U.S. is harvested, gathered, commingled, consolidated, and otherwise shipped from thousands of farms from which it is cultivated, harvested and passed through local, regional, and terminal distribution centers. In order to maintain the stability of the corn marketing system and its integrity, it is essential that the U.S. corn supply and U.S. corn exports maintain the highest standards of purity and integrity. Prior to the incidents giving rise to this lawsuit, the U.S. corn market maintained a reputation for such purity and integrity. Now, due to Syngenta's premature release of VIPTERA corn, sale of U.S. corn previously exported to China has ceased. China now refuses to import U.S. corn, corn grown, harvested and marketed by farmers and landowners such as the Plaintiffs and those similarly situated.

4. Plaintiffs and those similarly situated have incurred losses arising from the rejection of U.S. grown corn by export markets. They have sustained damage to their farmland and entire farming operations. And because the substantial portion of the U.S. corn crop is exported annually, the United States ability and limitations of corn exports deeply impacts corn price levels, including domestic prices in the corn market. Due solely to Syngenta's release of VIPTERA,

Plaintiffs and those similarly situated have incurred, and will continue to incur, substantial losses arising from the loss of export markets in amounts that have yet to be fully determined, but are far in excess of this Court's jurisdictional amounts for diversity jurisdiction.

5. Syngenta is, among other things, in the business of developing and selling in this district, in North Carolina and throughout the U.S., corn seed with certain genetically modified traits. After development, Syngenta then licenses corn seed with multiple genetically enhanced features, called "trait stacks," to seed manufacturers, including Syngenta subsidiaries.

6. The primary focus of this case is Syngenta's corn containing the MIR162 trait, utilized in the VIPTERA and Agrisure DURACADE™ ("DURACADE") trait stacks. DURACADE is Syngenta's second generation of MIR162 corn and was released, sold and distributed for planting in 2014. Over seventy (70) varieties of corn utilize the MIR162 trait to produce a protein that results in insect resistance. These corn varieties are commonly referred to as VIPTERA corn and DURACADE corn, representing the particular traits the corn will express.

7. Plaintiffs' harm and consequent damages, and the harm and damages of those similarly situated to Plaintiffs arise primarily, if not solely, from Syngenta's intentional and reckless release of VIPTERA and DURACADE into the

U.S. market prior to Syngenta obtaining approval for MIR162 import into China and other countries.

8. VIPTERA corn has been grown, licensed, marketed, sold, and/or otherwise disseminated in the United States since early 2009. Despite this, as of the time of filing this Complaint, crops or products containing MIR162 lacked approval for import into China (among other countries), and China refuses to accept corn containing MIR162.

9. Although it lacked approval to import corn or other products containing MIR162 into China, Syngenta nevertheless misinformed farmers such as the Plaintiffs and those similarly situated, grain elevators, grain exporters, landowners, Syngenta's own investors, the farming community and the general public, leading all to believe that approval from China was imminent. For example, during Syngenta's first quarter 2012 earnings conference call, Syngenta CEO Michael Mack stated "[t]here isn't outstanding approval for China, *which we expect to have quite frankly within the matter of a couple days . . .* we know of no issue with that whatsoever" *Exhibit A*, Transcript of Syngenta's First Quarter 2012 Earning Conference Call Transcript (emphasis added).

10. Contrary to Syngenta's affirmative misstatements, MIR162 was not approved for import by China in 2012 and remains unapproved.

11. Despite knowing MIR162 has never been approved for import into

China, Syngenta created and distributed forms and documents that imply MIR162 is accepted in China. Syngenta's "Request Form for Biosafety Certificate Issued by the Chinese Ministry of Agriculture" states, "Biosafety Certificates for the following transgenic event(s) were issued to Syngenta Seeds AG . . . by the Ministry of Agriculture (MOA) of the People's Republic of China (PRC)." Syngenta's request form includes MIR162 among approved genetically modified traits, even though MIR162 is not approved. *See Exhibit B*, Syngenta's Request Form For Biosafety Certificate(s) Issued by the Chinese Ministry of Agriculture.

12. *Exhibit B*, the Syngenta form, further states: "The requested Biosafety Certificates will be provided to Recipient to assist Recipient in obtaining required authorization for shipments containing the above marked Corn Product(s) into China." Syngenta's form is flagrantly deceptive, and deceives those like the Plaintiffs and those similarly situated because MIR162 has never been approved for import into China.

13. Plaintiffs and those similarly situated relied upon the statements in this and similar forms from Syngenta, and Syngenta omitted material information while marketing its seeds to the Plaintiffs and those similarly situated when it failed to disclose that MIR162 has never been approved for import into China, which was set to be one of the largest, if not the largest, importers of corn in the world

14. In November 2013, shipments of corn containing MIR162 arrived in China. These shipments were rejected because MIR162 was present and not approved for import. Since this initial rejection, China has continued to reject shipments of corn due to the MIR162 contamination caused by Syngenta. In fact, the widespread nature of MIR162 contamination has, for all intents and purposes, shutdown the 2014 U.S. corn export market to China, causing billions of dollars of damages to U.S. exporters, including farmers, farm landowners and farming entities.

15. It is also without serious dispute that Syngenta knew the potential for catastrophic damage when unapproved traits are released prematurely. The NGFA and NAEGA advised:

U.S. farmers, as well as the commercial grain handling and export industry, depend heavily upon biotechnology providers voluntarily exercising corporate responsibility in the timing of product launch as part of their product stewardship obligation. Technology providers must provide for two critical elements: First maintaining access to key export markets like China, or for that matter any market like China that has a functional, predictable biotech-approval process in place; for restricted marketability of their products based upon approval status in major markets. The negative consequences of overly aggressive commercialization of biotech-enhanced events by technology providers are numerous, and include exposing exporting companies to financial losses because of cargo rejection, reducing access to some export markets, and diminishing the United States' reputation as a reliable, often-preferred supplier of grains, oilseeds and grain products. Premature commercialization can reduce significantly U.S. agriculture's contribution to global food security and economic growth. Putting the Chinese and other markets at risk with such aggressive commercialization of biotech-enhanced events is not

in the best interest of U.S. agriculture or the U.S. economy.

Exhibit C, NGFA and NAEGA Joint Statement on Media Reports of Lawsuit Involving Syngenta's Agrisure VIPTERA™ Corn (MIR162).

16. According to the National Grain and Feed Association, Syngenta's premature release of VIPTERA corn cost the U.S. corn market a minimum of \$1 Billion - and up to \$3 Billion - due to the rejection and resulting seizures of U.S. containers and cargo ships transporting U.S. corn to China. *Exhibit D*, Legal Obligations and Potential Market Impacts Associated with Biotech-Enhanced Seeds Producing Grain Not Approved for Import into US. Export Markets.

17. Syngenta's motivation in prematurely releasing VIPTERA corn is purely profit driven, placing Syngenta's profits first and foremost ahead of the U.S. Corn interests, including but not necessarily limited to the Plaintiffs and those similarly situated. Upon information and belief, VIPTERA corn is presently approximately 25% of Syngenta's corn portfolio. In 2013, Syngenta's corn sales were over \$3.5 billion. *Exhibit E*, Syngenta's Annual Report, Form 20-F, Pg. 13, filed with the Securities and Exchange Commission on February 13, 2014.

18. And at present, Syngenta nevertheless continues its irreparable damage to U.S. exports of corn to China, although Syngenta either knew or should have known, or actually knows, that VIPTERA corn would and now has crippled exports of corn to China. Syngenta likewise knew or should have known of the

devastating effect of its release of MIR162 because, as Syngenta states in its Bio Product Launch Policy, "We will conduct market and trade assessments to identify key import markets for all of our biotech products prior to product commercialization." *See*, www.syngentabiotech.com/biopolicy.aspx (as of Sept. 11, 2014). Nevertheless, with such knowledge, Syngenta released its MIR162 in reckless disregard of the consequences from which malice may be inferred, and punitive damages should be assessed to punish Syngenta and deter others from such outrageous, selfish conduct in utter disregard of the damage to those such as the Plaintiffs and those similarly situated.

19. Despite the above, Syngenta continues its conduct by releasing a second version of MIR162 corn, DURACADE, once again without import approval from China.

20. Concerned about another premature release and given the damage Syngenta singlehandedly caused to the corn export market with its premature release of VIPTERA corn, the National Grain and Feed Association ("NGFA") and North American Export Grain Association ("NAEGA") released a joint statement to Syngenta requesting that Syngenta stop the release of DURACADE corn, so that it would stop the cycle of rejection and damage.

21. In that statement, the two organizations stated:

NAEGA and NGFA are gravely concerned about the serious economic harm to exporters, grain handlers and, ultimately,

agricultural producers - as well as the United States' reputation to meet its customers' needs - that has resulted from Syngenta's current approach to stewardship of VIPTERA. Further, the same concerns now transcend to Syngenta's intended product launch plans for DURACADE, which risk repeating and extending the damage. Immediate action is required by Syngenta to halt such damage.

Exhibit F, Joint Statement Issued by NGFA and NAEGA Regarding Letter to Syngenta Requesting Suspension of Commercialization Activities of Syngenta's Agrisure VIPTERA® and DURACADE® Corn.

22. Yet, despite the joint petitions and pleas from the NGFA and NAEGA, Syngenta released DURACADE. This second premature release further jeopardized the Chinese import market, as DURACADE contains not only unapproved MIR162, but also other unapproved traits. Contamination of corn with these additional genetically modified ("GM") traits, as set forth more fully below, will continue the rejection of U.S. corn shipments to China.

23. Plaintiffs are North Carolina corn farmers in the business of owning and cultivation of farmland, planting, growing, and harvesting corn with the expectation of ultimately selling the corn they grow, just as those similarly situated. Plaintiffs and those similarly situated, have been damaged, at least, by: 1) Syngenta's premature release of VIPTERA corn into the U.S. corn and corn seed supply which has destroyed the export of U.S. corn to China; 2) Syngenta's premature release of DURACADE corn into the U.S. corn and corn seed supply which, again, has effectively foreclosed U.S. exports of corn to China; 3)

Syngenta's materially misleading statements relating to the approval status of MIR162 in China upon which Plaintiff and those similarly situated relied or upon which Syngenta failed to disclose material facts that MIR162 was not approved in China; 4) and upon information and belief, Syngenta's widespread contamination of the U.S. corn and corn seed supply with MIR162 which will continue to result in the destruction of the U.S. corn export market to China for years to come.

24. Plaintiffs for themselves and all others similarly situated seek relief for compensatory, consequential, and punitive damages, and injunctive relief arising from, inter alia:

a. Syngenta's harm to Plaintiffs caused by contamination of the general U.S. corn and corn seed supply in the form of, inter alia, (i) inability to export corn to China, (ii) diminished corn and corn product prices resulting from the loss of the entire Chinese corn import market.

b. Syngenta's premature release of VIPTERA corn into the U.S. corn supply, knowing that once VIPTERA corn was released, it would be commingled with and would contaminate the U.S. corn supply resulting in the inability to export to markets that had not approved products containing MIR162 (such as China);

c. Syngenta's encouragement of farmers to plant VIPTERA corn in such a manner that it would contaminate the U.S. corn supply, so that U.S. corn could not be sold to markets that had not approved products containing MIR162;

d. Syngenta's failure, either by itself or through its agents, to adequately warn VIPTERA corn farmers of the necessary precautions and limitations required to prevent contamination to non-VIPTERA corn via cross-pollination, including the necessity for carefully cleaning all equipment, storage bins and related farm implements;

e. Syngenta's failure, either by itself or through its agents, to adequately warn DURACADE corn farmers of the necessary precautions and limitations required to prevent contamination to non- DURACADE corn via cross-pollination;

f. Syngenta's testing, growing, storing, transporting, marketing, selling, disposing, or otherwise disseminating VIPTERA corn in light of knowledge that it was essentially impossible to prevent contamination of other non-VIPTERA corn via cross-pollination;

g. Syngenta's testing, growing, storing, transporting, marketing, selling, disposing, or otherwise disseminating DURACADE corn in light of knowledge that it was essentially impossible to prevent contamination of other non- DURACADE corn via crosspollination;

h. Syngenta's marketing, selling, or otherwise disseminating VIPTERA corn in light of knowledge that it was essentially impossible to prevent contamination of other non-VIPTERA corn via cultivation, harvesting, handling, storage, and transportation, resulting in damages from loss of sales and to equipment;

i. Syngenta's marketing, selling, or otherwise disseminating DURACADE corn in light of knowledge that it was essentially impossible to prevent contamination of other non-DURACADE corn via cultivation, harvesting, handling, storage, and transportation;

j. Syngenta's materially false statements and representations made regarding the regulatory-approval status of MIR162 and VIPTERA corn or, in the alternative, Syngenta used deception, fraud or false pretense, or through failure disclose material facts, through concealment or suppression of material facts, omission, deception, fraud or false pretense of material facts in connection with the regulatory-approval status of MIR162 and VIPTERA corn with the intent that the Plaintiffs and those similarly situated, along with the corn farming industry rely upon their concealment, suppression or omission of material facts, all of which was a proximate cause of the Plaintiffs damages and damages to those similarly situated; and

25. Syngenta made the conscious decision in reckless disregard of the consequences from which malice may be inferred that it was more profitable to

speed VIPTERA to the market, maximize and extract a huge profit, and recoup its research costs, even though it knew the premature release of VIPTERA corn would prevent U.S. corn from being sold to markets such as China. By doing this, Syngenta crippled the 2013 and 2014 corn export markets to China. Further, on top of devastating the entire corn market and inflicting at least \$1 billion in economic damage, Syngenta prematurely released another MIR162 corn hybrid, further devastating and inflicting widespread harm to the U.S. corn market, and all causing lost sales and income to the Plaintiffs.

PARTIES

26. Plaintiffs are engaged in the business of farming, including ownership and cultivation of farmland whereby corn is planted, grown, harvested and ultimately sold. Plaintiffs' income is premised upon the ultimate sale of the crops grown on their farmland, here corn. Plaintiffs have never purchased MIR162 corn from Syngenta.

27. Defendant Syngenta AG is a corporation organized and existing under the laws of Switzerland with its principal place of business at Schwarzwaldallee 215, 4058 Basel-Stadt, Switzerland.

28. Defendant Syngenta Crop Protection AG is a corporation organized and existing under the laws of Switzerland with its principle place of business at Schwarzwaldallee 215, 4058 Basel-Stadt, Switzerland.

29. Defendant Syngenta Corporation is a Delaware corporation with a principle place of business at 3411 Silverside Road #100, Wilmington, Delaware 19810-4812 and may be served through its registered agent, CT Corporation System, 150 Fayetteville St., Box 1011, Raleigh, North Carolina 37601.

30. Defendant Syngenta Seeds, Inc. is a Delaware corporation which, upon information and belief, is doing business in North Carolina under the fictitious name of Novartis Seeds, Inc., with its principle place of business at 11055 Wayzata Boulevard, Minnetonka, Minnesota 55305-1526, and may be served through its registered agent, CT Corporation System, 150 Fayetteville St., Box 1011, Raleigh, North Carolina 37601.

JURISDICTION AND VENUE

31. This Court has subject matter jurisdiction pursuant to 28 U.S.C. §§ 1331 and 1332 and supplemental jurisdiction pursuant to 28 U.S.C. §1367(a).

32. This Court has personal jurisdiction over the Defendants because Defendants regularly and systematically conduct business in this District, including, at minimum, the marketing and sale of VIPTERA and DURACADE corn within this District.

33. Venue is proper in this District pursuant to 28 U.S.C. § 1391(b) and (c) because Defendants have and continue to market, sell, and/or otherwise disseminate VIPTERA and DURACADE corn in this District, and because

Defendants are actively doing business in this District.

34. Venue is further proper because a substantial part of the property, particularly the farming operations and the farmland that is the subject of and forming the basis of this action, is situated in this District, and a substantial part of the events or omissions giving rise to this action occurred in this District.

FACTUAL ALLEGATIONS

The United States Corn Export Market

35. Corn is the most widely-cultivated grain crop in the U.S. The United States is a major player in the world corn trade market, and is the world's largest producer and exporter of corn. Approximately 80 million acres of farmland is devoted to growing corn. Nearly 20% of U.S. corn is exported to other countries.

36. The premature release of VIPTERA corn has hurt the U.S. corn market in many ways.

37. The NGFA estimated that the premature release of VIPTERA corn caused corn prices to decline by \$0.11 per bushel. *Exhibit G, Lack of Chinese Approval for Import of U.S. Agricultural Products Containing Agrisure VIPTERA™ MIR162: A Case Study on Economic Impacts in Marketing Year 2013/14.*

38. The U.S. corn marketing system, generally, is commodity-based and gathers, commingles, and ships corn from hundreds of thousands of farmers just

like Plaintiffs together with those similarly situated, through local, regional, and terminal grain elevators. Grain elevators and other corn storage and transportation facilities are generally not equipped to test and segregate corn varieties, and to undertake testing and segregation at these facilities causes disruption and expense.

39. After rejections of U.S. corn by China started in late 2013, Plaintiffs corn prices plunged and continue downward.

40. VIPTERA corn was developed by Syngenta by using modern biotechnology techniques. Syngenta modified the corn by inserting genetic material from a bacterium, *Bacillus thuringiensis* ("Bt"). Within the corn-biotechnology industry, corn manipulated in this fashion is commonly referred to as "*Bt corn*."

41. The specific genetic material inserted into the genome of VIPTERA corn allows the genetically altered corn to produce certain proteins including Cry1Ab, mCry3A, and Vip3A.

42. These proteins have insecticidal properties which, according to Syngenta, "controls more insects than any other trait stack on the market" including Black Cut Worm, Corn Earworm, European Corn Borer, Fall Armyworm, Western Bean Cutworm, and Stalk Borer.

43. VIPTERA's insecticidal protection comes from the Vip3A protein, a "vegetative insecticidal protein," which binds to the insect's midgut epithelium and

forms pores, killing the insect before further crop damage may be done.

44. Syngenta invested approximately \$200 million and five to seven years developing VIPTERA corn.

45. Notably, VIPTERA corn is protected by Syngenta patent(s) giving Syngenta the right to exclude others from selling products with the VIPTERA corn traits. This is part of its motivation in pushing this product prior to approval from China (i.e., Syngenta is attempting to maximize its period of exclusivity when no others can sell VIPTERA corn).

46. As a bio-engineered product, VIPTERA corn was subject to U.S. and foreign regulatory approval prior to cultivation or import.

47. Syngenta had registered VIPTERA corn as a pesticide with the Environmental Protection Agency.

48. VIPTERA was deregulated by the U.S. Department of Agriculture in April 2010.

49. In the spring of 2010, Syngenta made the decision to release VIPTERA corn commercially for the 2010/11 growing season. This release came at a time when VIPTERA corn lacked approval by import markets such as China, Japan, and the European Union.

50. At the time of release, Syngenta believed and reassured the public that approval in Japan and the European Union was imminent. Syngenta, however,

was silent regarding China.

51. Japan and the European Union have since approved the importation of VIPTERA corn. China, however, has not. Despite this, Syngenta encouraged and still encourages farmers to grow VIPTERA corn.

52. To date, China has still not approved the importation of any product containing MIR162.

Contamination of the United States Corn Supply

53. Commingling different varieties of corn is always a risk during planting, harvesting, drying, storage, and transportation of corn. Thus, once released, a corn variety will, without adequate protections, contaminate the broader corn supply.

54. Despite contamination risks, Syngenta offered farmers a "side-by-side program" which encouraged farmers to plant VIPTERA corn side-by-side with other corn seed.

55. Rather than instruct its customers on how to limit the contamination of VIPTERA corn into the broader corn supply, Syngenta's side-by-side program encouraged farmers to not take precautions. By doing this, Syngenta helped spread the amount of MIR162 that would appear in the U.S. corn supply, thus putting at risk Chinese exports.

56. Syngenta knew or should have known that encouragement of side-by-

side planting of VIPTERA and non-VIPTERA corn would inevitably lead to commingling.

57. Syngenta knew or should have known that this commingling would result in rejected shipments of U.S. corn by Chinese regulatory officials.

58. In short, Syngenta knew or should have known of the high risk and consequences of commingling VIPTERA corn with the broader corn supply. Syngenta encouraged farmers to disregard practices designed to prevent commingling and encouraged side-by-side planting of VIPTERA and non-VIPTERA corn, essentially ensuring the contamination by commingling.

59. Corn replicates by cross-pollination from one plant to another. Pollen from corn has been shown to "drift" over considerable distances and cross-breed with corn from other plants.

60. The corn resulting from cross-pollination can express traits from the pollen-donating plant.

61. Those knowledgeable in the field suggest that, at a minimum, pollen can travel 200 feet. Some studies have found that cross-pollination cannot be eliminated, even at a distance of one third of a mile. *Exhibit H*, Peter Thomison, Managing "Pollen Drift" to Minimize Contamination of Non-GMO Corn, The Ohio State University Extension Fact Sheet, available at <http://ohioline.osu.edu/agf-fact/0153.html> (last visited Sept. 9, 2014).

62. Without adequate precautions, neighboring corn fields will exchange pollen.

63. The Thomison article states "[e]ach corn plant is capable of producing 4 to 5 million pollen grains." *Id.*

64. Further, the Thomison article states "even if only a small percentage of the total pollen shed by a field of corn drifts into a neighboring field, there is considerable potential for contamination through cross pollination." *Id.*

65. Syngenta, as a leader in the field of corn biotechnology, understood or should have understood the effects of contamination by cross-pollination at the time of the release of VIPTERA corn.

66. Syngenta recognized in its "Agrisure™ Traits Stewardship Guide" that "[a] normal occurrence in corn production is cross-pollination ... " and "[i]t is not possible to achieve 100% purity of seed or grain in any corn production system and a certain amount of adventitious pollen movement will occur." *Exhibit I*, Syngenta 2011 Agrisure™ Traits Stewardship Guide.

67. Other seed producers agree. DuPont Pioneer published a fact sheet stating "Remember that achieving 100% purity is virtually impossible in seed or grain production." *Exhibit J*, DuPont Pioneer Maximizing Genetic Purity of Corn in the Field, available at https://www.pioneer.com/CMRoot/Pioneer/US/products/stewardship/genetic_purity.pdf (last visited Sept. 9, 2014).

68. Upon information and belief, Syngenta encouraged cross-pollinating of VIPTERA corn with non-VIPTERA corn and its "side-by-side program" because it knew that cross-pollination was certain to occur. Unfortunately, this led to additional contamination of the U.S. corn supply with the MIR162 trait.

69. To summarize, Syngenta knew that pollen drift was certain to occur and encouraged farmers to plant VIPTERA corn in a way that promoted cross-pollination and thus contamination of the U.S. corn supply.

VIPTERA – A Continuing Controversy

70. After the 2011 planting season, but before the 2011 harvest season, Bunge North America, Inc. ("Bunge"), a grain elevator and handler based in St. Louis, Missouri, posted signs and distributed materials stating that VIPTERA corn would not be accepted during the harvest season.

71. Bunge cited the lack of Chinese import approval as its reason for not accepting VIPTERA corn.

72. In response, Syngenta sued Bunge in the Northern District of Iowa, seeking, inter alia, preliminary and permanent injunctions requiring Bunge to stop posting materials regarding its refusal to accept VIPTERA corn, and, more importantly, requiring Bunge to accept VIPTERA corn at its facilities. Complaint, Syngenta Seeds, Inc., v. Bunge North America, Inc., No. 5: 11-cv-04074-MWB, (N.D. Iowa Aug. 22, 2011) ECF No. 1.

73. Bunge responded to the lawsuit stating" ... we are surprised and disappointed that Syngenta has taken an action which could put at risk a major export market for U.S. corn producers [-] China." Further, in the same statement, Bunge made clear:

Bunge's decision not to accept Agrisure VIPTERA is consistent with the North American Export Grain Association's (NAEGA) policy to advocate that technology providers receive all major international approvals for a trait prior to seed sales. The grain export industry, which includes Bunge, notified Syngenta more than a year ago that China is considered a major export market.

Exhibit K, Statement of Soren Schroder, President and CEO of Bunge North America, <https://www.bungenorthamerica.com/news/28-bunge-responds-to-syngenta-suit> (last visited August 21, 2014).

74. Syngenta's request for a preliminary injunction was denied. Memorandum Opinion and Order: Denying Motion for Preliminary Injunction, Syngenta Seeds, Inc., v. Bunge North America, Inc., No. 5:11-cv-04074-MWB, (N.D. Iowa Sept. 26, 2011) ECF No. 42.

75. Major grain handlers including Bunge, Archer Daniels Midland, Cargill, and Consolidated Grain and Barge still refuse to accept VIPTERA corn, as preventing commingling is essentially impossible.

The Chinese Imports Market

76. In the past, Japan and Canada were considered the major corn import markets. Accordingly, many biotech-trait commercialization decisions were made

based on approval obtained from these two countries.

77. However, in recent years, China has become a major importer of corn and corn products. A recent study by the USDA shows that during the 2012/13 import year China imported five times more corn than Canada. <http://www.usda.gov/oce/commodity/wasde/latest.pdf> (last visited Sept. 11, 2014).

Table 1
Corn Imports by Country by Trade Year
(Thousand Metric Tons)

| | 2009/10 | 2010/11 | 2011/12 | 2012/13 | 2013/14 (estimated) |
|---------------|----------------|----------------|----------------|----------------|--------------------------------|
| Japan | 15,971 | 15,648 | 14,892 | 14,412 | 15,500 |
| China | 1,296 | 979 | 5,231 | 2,702 | 3,500 |
| Canada | 2,100 | 950 | 870 | 480 | 400 |

Data compiled from USDA World Agricultural Supply and Demand Estimates available at <http://www.usda.gov/oce/commodity/wasde/>

78. China, having not approved the importation of VIPTERA corn, maintains a strict zero tolerance policy regarding contamination of corn imports with corn containing MIR162.

79. This means that any detection of MIR162 in a shipment to China could result in rejection of that shipment.

80. Syngenta had knowledge of China's zero-tolerance policy prior to the commercialization of VIPTERA corn.

81. Further, Syngenta had knowledge that there was no means of detecting a "zero" level of MIR162 in a given sample. At least, Charles Lee -

Syngenta's North American Head of Corn - stated, when asked about potential detection methods, "Yeah, nothing can detect to zero." *Exhibit L*, Deposition of Charles R. Lee - Sept. 7, 2011, Syngenta Seeds, Inc., v. Bunge North America, Inc., No. 5:11-cv-04074-MWB, (N.D. Iowa Sept. 15, 2011) ECF No. 32-6, 92:21. In other words, there is always a risk that if a corn shipment is tested in the U.S. and is negative for MIR162, a second test at port could result in a positive for MIR162.

82. Even further, when questioned about the decision-making process to commercialize VIPTERA corn, Mr. Lee stated that commercialization was premised on U.S. deregulation and Japanese and Canadian approval. *Id.* at 82:15-20.

83. Mr. Lee stated in his deposition "we operate on the principle that we need U.S., Japan and Canada. And so once we have those approvals, we do commercialization of the product" *Id.* at 90:10-13.

84. Therefore, Syngenta recognized that it is improper to rush a product to market without first receiving approvals from certain other countries to which U.S. corn is exported. Despite this knowledge, it did not wait for Chinese approval.

85. There was no requirement that Syngenta commercialize VIPTERA corn at this time. However, as stated by Mr. Lee, Syngenta was "trying to recoup

[its] costs as an organization." Further, Syngenta "[l]ike anybody, [wanted] to derive some income from [its] products." *Id.* At 70:22-71:13.

86. Syngenta also commercialized VIPTERA corn before major market approval as "[y]ou have to operate in the nongeneric period [of Syngenta's patent covering VIPTERA corn]. You like to optimize that period." *Id.* at 72:3-6.

87. On or about November 2013, cargo shipments of U.S. corn were rejected by Chinese regulatory officials after testing positive for VIPTERA corn.

88. On December 24, 2013, the General Administration of Quality Supervision, Inspection and Quarantine of China issued a warning notification strengthening the inspection and supervision for the import of GMO feed materials. This notification stated the impetus was that Shanghai Chinese Inspection and Quarantine Service ("CIQ") had detected MIR162. The December 24 notification indicated that all batches of corn would now be tested at the Chinese ports for MIR162, and that any cargo which tested positive for MIR162 would be returned or destroyed.

89. After this notification, corn transactions were at increased risk.

90. Also, since China initially only required certification from the seller/exporter that the shipped corn did not contain MIR162, a negative test result from the seller/exporter was sufficient. This allowed predictability in that customers in China would know from the beginning of a contract that the corn

products would clear Chinese customs.

91. Now that testing occurred at Chinese ports, an increased risk was placed on export contracts, because, as Syngenta testified, there was no way to detect a "zero" level of MIR162 (i.e., a negative test of a container in the U.S. could still result in a positive test in China). This caused an initial amount of Chinese customers to walk away from their contracts, placed great deal of uncertainty on the market, and dramatically hurt corn prices.

92. An increased frequency of corn shipments were testing positive, and in July 2014, China again strengthened its policy regarding MIR162.

93. Since November of 2013 (i.e., the positive tests for MIR162 in China), Chinese imports for U.S. corn have fallen by an estimated 85%.

94. This market shift comes as China was expected to import a record high 7 million tons of U.S. corn according to estimations made by the U.S. Department of Agriculture.

95. The rejection of U.S. corn imports has and continues to negatively impact the global corn market.

96. Syngenta knew or should have known that disruption to the Chinese import market would influence the global corn market.

97. Syngenta knew or should have known that contracts between grain exporters and Chinese corn buyers would be negatively affected if MIR162 was

found in grain exports to China.

Syngenta's Admissions Regarding MIR162

98. Syngenta knew or should have known of the damage that the rejection of corn by China would cost. For example, the un rebutted evidence at the hearing on Syngenta's Motion for Preliminary Injunction indicated that the redirection costs for a rejected shipment of contaminated corn could be anywhere from \$4 million to \$20 million for a single shipment. Memorandum Opinion and Order Regarding Plaintiff Motion for Preliminary Injunction, *Syngenta Seeds, Inc., v. Bunge North America, Inc.*, No. 5:11-cv-04074-MWB, (N.D. Iowa Sept. 26, 2011) ECF No. 42, at 12 (emphasis added).

99. Syngenta also knew or should have known that releasing MIR162 prior to Chinese approval would affect corn prices.

100. In Syngenta's 2010 Full Year Results, CEO Michael Mack ("Mr. Mack") stated that Chinese "import requirements alone influence global commodity prices." *Exhibit M*.

101. During Syngenta's 2011 Half Year Earnings Report, Mr. Mack again commented on the importance of the Chinese market, stating that China "continues to have the greatest impact on world markets, with increasing imports not just of soybeans but also now of corn." *Exhibit N*.

102. In response to a question during the first quarter 2012 earnings

conference call regarding the status of Chinese approval of VIPTERA, Mr. Mack stated "[t]here isn't outstanding approval for China, which we expect to have quite frankly within the matter of a couple days . . . we know of no issue with that whatsoever" *Exhibit A*.

103. Yet as set forth in the preceding paragraphs: the CEO of Syngenta publicly stated in 2012 that approval of VIPTERA was days away.

104. Mr. Mack's statement was made as an advertisement for VIPTERA corn.

105. Mr. Mack refers specifically to VIPTERA corn.

106. Mr. Mack had an economic motivation for making this statement—continued sales of VIPTERA corn.

107. Mr. Mack's statement was disseminated sufficiently to constitute promotion within the grain industry.

108. This statement, and others like this, dangerously impacted the corn market by, for example, encouraging 1) farmers to plant MIR162, 2) grain elevators to accept and comingle MIR162 with other grains, and 3) exporters to purchase and ship products containing MIR162.

109. Obviously, Syngenta was incorrect with its "matter of a couple days" prediction.

110. In 2014, Syngenta knew or should have known that China would not

approve MIR162 in time for 2014 planting. For example, Mr. Mack stated during Syngenta's first quarter 2014 conference call "I think it is fair to say at this point in time that we don't have—that we will not have any approval before the start of the season. That's for sure." *Exhibit O*.

111. During Syngenta's most recent earnings conference call—second quarter 2014—Mr. Mack made the following statements regarding Chinese approval of VIPTERA corn:

You ask about VIPTERA and our regulatory issues. Actually, I think this is a regulatory matter in China as opposed to any regulatory matter with Syngenta. The delays coming out of China are such that people just aren't really understanding right now even what the process is.

We don't have it in hand and I wouldn't want to say any more about when we might have it in hand, beyond to say that there is no question; there is no technical question right now waiting from the Chinese about it, and it's been approved already in virtually every other market. So, we'll see what happens over the coming weeks, months, quarters.

Exhibit P.

112. This statement confirms that Syngenta recognizes there is no end in sight for problems with exports to China due to its MIR162 products. Despite this, Syngenta continues to sell MIR162 products, as well as launch new GMO products, none of which have been approved by China. In doing so, Syngenta knows or should know that it will continue to destroy U.S. exports of corn to China.

113. Further, and despite its 2014 statements as to uncertainty in China, Syngenta misled exporters into believing products containing MIR162 would be accepted in China.

114. On its website, Syngenta has offered and continues to offer a form entitled "Request Form for Biosafety Certificate Issued by the Chinese Ministry of Agriculture." *See, e.g.,* <http://www3.syngenta.com/country/us/en/agriculture/Stewardship/Documents/ChinaSafetyCertificateApplication.pdf> (last visited Sept. 9, 2014).

115. This form states, "Biosafety Certificates for the following transgenic event(s) were issued to Syngenta Seeds AG . . . by the Ministry of Agriculture (MOA) of the People's Republic of China (PRC)." One of the "transgenic event(s)" listed on this Syngenta form is MIR162.

116. The Syngenta form continues "The requested Biosafety Certificates will be provided to Recipient to assist Recipient in obtaining required authorization for shipments containing the above marked Corn Product(s) into China," and additionally states, "The Biosafety Certificate(s) provided allows importation of the above marked Corn Product(s) as raw materials for processing for food and feed use only, not for any research purpose or cultivation purpose."

117. The implication of this form is clear: if completed (by, for example, an exporter), Syngenta will issue Biosafety Certificates, which will ensure the

cargo can enter into China.

118. Syngenta's request form was released as an advertisement for VIPTERA corn, as it indicates that products containing MIR162 may be imported into China.

119. Syngenta's request form refers specifically to MIR162, the key trait in VIPTERA corn.

120. Syngenta had an economic motivation to include MIR162 on its request form, even though Syngenta knew MIR162 was not approved for import into China - continued sales of VIPTERA corn.

121. Syngenta's form was disseminated sufficiently to constitute promotion within the seed sales industry.

122. The statements made by Syngenta officials above show Syngenta knew that while the other Corn Products/transgenic events identified on this form were approved in China, MIR162 was not.

PLAINTIFFS' CLAIMS FOR RELIEF

COUNT I

VIOLATION OF LANHAM ACT – § 15 U.S.C. 1125(a)(1)(B)

123. Plaintiffs incorporate by reference Paragraphs 1-122 as though fully set forth herein.

124. The Lanham Act, 15 U.S.C. § 1125(a), provides in pertinent part:

(1) Any person who, on or in connection with any goods or

services, or any container for goods, uses in commerce any word, term, name, symbol, or device, or any combination thereof, or any false designation of origin, false or misleading description of fact, or false or misleading representation of fact, which—

(B) in commercial advertising or promotion, misrepresents the nature, characteristics, qualities, or geographic origin of his or her or another person's goods, services, or commercial activities, shall be liable in a civil action by any person who believes that he or she is or is likely to be damaged by such act.

125. Syngenta's statements and commentary made to the press, statements on the internet, during quarterly conference calls, and incorporated into Syngenta's forms, which, inter alia, represent VIPTERA corn is or would imminently be approved for import into China, as alleged above, are materially false statements that are and continue to be likely to cause confusion and mistake as to the nature, characteristics, and qualities of VIPTERA corn.

126. Syngenta's statements were made as an advertisement for VIPTERA corn.

127. Syngenta's statements refer specifically to VIPTERA corn.

128. Syngenta had an economic motivation for making its statements—sales of VIPTERA corn.

129. Syngenta's statements were likely to influence purchasing decisions.

130. Syngenta's statements were widely distributed, which is, at least, sufficient to constitute promotion within the grain industry.

131. Upon information and belief, Plaintiffs and the farming community

have relied on Syngenta's material misrepresentations.

132. Plaintiffs have and continue to be damaged by Syngenta's material misrepresentations.

133. Plaintiffs' damages were proximately caused by Syngenta's acts.

134. Syngenta indicated Chinese approval of MIR162 was imminent, when in fact it was not, and Syngenta's "Certificate for Biosafety Certificate Issued by the Chinese Ministry of Agriculture" falsely represents that VIPTERA corn was approved for import into China. *See, Exhibit B.*

135. Syngenta's acts constitute the use of false descriptions and false representations in interstate commerce in violation of the § 43(a) of the Lanham Act, 15 U.S.C. § 1125(a).

COUNT II PUBLIC NUISANCE

136. Plaintiffs incorporate by reference Paragraphs 1-135 as though fully set forth herein.

137. Through the conduct alleged above, Syngenta has created a public nuisance by causing widespread contamination of the U.S. corn supply with the MIR162 trait.

138. This unreasonable interference is imposed on the community at large and on a considerable diverse number of persons and entities. It arises from Syngenta's testing, growing, storing, transporting, selling, disposing, or otherwise

disseminating VIPTERA corn: (a) without adequate precautions to prevent contamination of the U.S. corn and corn seed supplies; (b) with the knowledge that VIPTERA corn would contaminate other corn; (c) with the knowledge that this contamination would likely affect the U.S. corn and corn seed supplies; or (d) with the knowledge that there was a substantial risk of contamination of corn and corn seed supplies earmarked for export.

139. Syngenta has unreasonably interfered with the public's right to expect compliance with the federal laws governing the testing, growing, storing, transporting, selling, disposing, or otherwise disseminating VIPTERA corn. Syngenta has further unreasonably interfered with the public's right to expect that the corn sold to the general public is free from contamination with VIPTERA corn as well as the public's right to be notified of whether the corn sold to the public is contaminated with genetically-modified organisms—including corn containing MIR162—so that the public has the freedom to choose to purchase and consume non-contaminated corn.

140. This interference is unreasonable in that it involves a significant interference with the public health, the public safety, the public peace, the public comfort, or the public convenience. It is also unreasonable in that it is proscribed by law, is of a continuing nature, and has produced a permanent or long-lasting effect.

141. Plaintiffs have suffered harm caused by Syngenta's public nuisance distinct from and different than that suffered by the general public in that, as described above, they have suffered business losses in the form of, among other things, the rejection of the crops by certain export markets, namely China.

142. This constitutes an unreasonable and substantial interference with rights common to the general public, restricted demand for their products and services in certain markets; and reduced prices for their corn in all markets.

143. In light of the surrounding circumstances, Syngenta knew or should have known that their conduct would naturally or probably result in injuries and damages to the Plaintiffs. Nevertheless, Syngenta continued such conduct in reckless disregard of or conscious indifference to those consequences from which malice may be inferred and, consequently, punitive damages should be assessed to punish and deter.

COUNT III COMMON LAW NEGLIGENCE

144. Plaintiffs incorporate by reference Paragraphs 1-143 as though fully set forth herein.

145. With respect to its testing, growing, storing, transporting, selling, disposing, or otherwise disseminating VIPTERA corn, Syngenta had a duty to utilize its professional expertise and exercise that degree of skill and learning ordinarily used under the same or similar circumstances by a person or entity in

Syngenta's business.

146. Syngenta breached this duty by failing to exercise the requisite degree of care in testing, growing, storing, transporting, selling, disposing, or otherwise disseminating VIPTERA corn to prevent it from contaminating the U.S. corn supply.

147. Upon information and belief, Syngenta further breached their duty by failing to notify the appropriate regulatory bodies and the public in a timely fashion after it first learned of the contamination of the U.S. corn supply with MIR162.

148. The damages incurred by Plaintiffs were or should have been foreseen by Syngenta as Syngenta understood the risks of releasing VIPTERA corn, including but not limited to, the near certainty of cross-pollination, risks of intentional or unintentional commingling of VIPTERA corn with non-VIPTERA corn, China's zero-tolerance policy for MIR162, and China's large, and growing, U.S. corn import market.

149. Syngenta breached its duties, as alleged above, breached the requisite standard of care owed to all foreseeable Plaintiffs and those similarly situated, and was therefore negligent.

150. Syngenta's breaches are a direct and proximate cause of the injuries and damages sustained by the Plaintiffs in amounts not yet fully determined but far in excess of any amounts necessary for diversity jurisdiction.

COUNT IV
FAILURE TO WARN

151. Plaintiff incorporates by reference Paragraphs 1-150 as though fully set forth herein.

152. Syngenta is strictly liable to the Plaintiffs resulting from its failure to warn about the dangers of planting, growing, harvesting, transporting, or otherwise utilizing VIPTERA corn.

153. Syngenta sold VIPTERA corn in the course of its business, as alleged above.

154. When planted, grown, harvested, transported or otherwise utilized as reasonably anticipated and without knowledge of its characteristics, VIPTERA corn was unreasonably dangerous at the time of its sale.

155. Syngenta did not give an adequate warning of the danger of planting, growing, harvesting, transporting, or otherwise utilizing VIPTERA corn.

156. Upon information and belief, VIPTERA corn was used in a reasonably anticipated manner.

157. Plaintiffs suffered injury and damages as a direct and proximate result of Syngenta's failure to provide an adequate warning regarding the dangers of planting, growing, harvesting, transporting, or otherwise utilizing VIPTERA corn at the time VIPTERA corn was sold.

158. In light of the surrounding circumstances, Syngenta knew or should

have known that their conduct would naturally or probably result in injuries to the Plaintiffs and class members.

159. Nevertheless, Syngenta continued such conduct in reckless disregard of or conscious indifference to those consequences from which malice may be inferred and punitive damages should likewise be assessed.

COUNT V TORTIOUS INTERFERENCE

160. Plaintiffs incorporate by reference Paragraphs 1-159 as though fully set forth herein.

161. Plaintiffs had business relationships whereby Plaintiffs would sell their corn to grain purchasers. These business relationships were memorialized by invoices, receipts, and other documents showing a consistent course of sales.

162. Plaintiffs had a reasonable expectation of economic gain resulting from the relationships with their grain purchasers. Plaintiffs reasonably expected to continue to sell corn from their farms to such companies, and that the price at which they would be able to do so would be based on marketplace conditions and would not be adversely affected by the contamination of the U.S. corn supply with corn seed products that were not approved in all major export markets. Plaintiffs rightfully maintained the expectation that such business relationships would continue in the future.

163. Syngenta knew that Plaintiff and other farmers had business

relationships with such grain elevators and supply companies in the normal chain of crop export and sales, and Syngenta was fully aware that Plaintiff and other farmers expected these business relationships to continue in the future.

164. Despite this knowledge, Syngenta made representations that deceived farmers and other consumers as to whether grain elevators and other supply companies would accept MIR162 corn, and deceived farmers and other consumers regarding the negative impact of MIR162 on U.S. corn prices. These misrepresentations, stated that MIR162 corn is or would imminently be approved for import into China.

165. Syngenta interfered with these prospective future business relationships through its conscious decision to bring MIR162 corn to the market. Syngenta knew, or should have known, that releasing MIR162 corn would lead to the contamination of all U.S. corn shipments and prevent U.S. corn from being sold in China, which had not granted import approval.

166. Syngenta's release of MIR162 corn has destroyed the export of U.S. corn to China and caused depressed prices for all domestic corn producers. Thus, Plaintiffs and others similarly situated are unable to sell their corn to grain elevators and supply companies at the price they reasonably expected to receive.

167. Syngenta intentionally interfered with Plaintiffs' prospective business relationships; and Syngenta knew the interference was certain or substantially

certain to occur as a result of its conduct in releasing MIR162 corn into the U.S. market.

168. Plaintiffs have been proximately damaged and continue to be damaged as a result of Syngenta's interference.

169. Syngenta's tortious conduct serves as a direct and proximate cause of the injuries and damages sustained by Plaintiffs and the others similarly situated.

CLASS ACTION ALLEGATIONS

170. Plaintiffs bring this action pursuant to Rules 23(a), 23(b)(2), and 23(b)(3) of the Federal Rules of Civil Procedure on behalf of itself and a class of persons or entities similarly situated.

171. Those similarly situated include persons and entities (excluding Syngenta and its officers, directors, and employees and all governmental entities) who, during the relevant time period grew, harvested or sold non-MIR162 corn and corn-related products on a commercial basis.

172. Plaintiffs assert claims against Syngenta, individually and on behalf of all class members for violations of the law as set forth below.

173. The requirements of Rule 23(a) are satisfied for the proposed class because the members of the proposed class are so numerous and geographically dispersed that joinder of all its members is impracticable. Although the exact number and identity of each class member is unknown at this time, there are

believed to be hundreds of potential class members nationwide. Therefore, the "numerosity" requirement of Rule 23(a)(1) is met.

174. The commonality requirement of Rule 23(a)(2) is satisfied because there are questions of law or fact common to Plaintiffs and the other members of the proposed class. Among those common questions of law or fact are:

a. whether Syngenta, through its acts or omissions, caused or allowed MIR162 to contaminate the U.S. corn and corn seed supplies;

b. whether Syngenta, through its acts or omissions, caused or allowed MIR162 to contaminate the U.S. DDGS supply;

c. whether Plaintiffs and the members of the proposed class have sustained or continue to sustain damages as a result of Syngenta's wrongful conduct, and, if so, the proper measure and appropriate formula to be applied in determining damages for the injuries sustained;

d. whether Plaintiffs and the members of the proposed class are entitled to compensatory, consequential, and exemplary damages; and

e. whether Plaintiffs and the members of the proposed class are entitled to declaratory, injunctive, or other equitable relief.

175. Plaintiffs' claims are typical of the claims of the proposed class that it seeks to represent, as described above, because they arise from the same course of conduct by Syngenta and are based on the same legal theories. Further, Plaintiffs seeks the same forms of relief for itself and the proposed class. Therefore, the "typicality" requirement of Rule 23(a)(3) is satisfied.

176. Because its claims are typical of the proposed class that Plaintiffs seeks to represent, Plaintiff has every incentive to pursue those claims vigorously.

Plaintiffs has no conflicts with, or interests antagonistic to, the farmers who have lost income and sustained other economic loss as a result of the loss of the China market. Plaintiffs are committed to the vigorous prosecution of this action, which is reflected in their retention of competent counsel experienced in complex and challenging litigation.

177. Plaintiffs' counsel satisfies the requirements of Rule 23 (g) to serve as counsel for the proposed class. Plaintiffs' counsel has (a) identified and thoroughly investigated the claims set forth herein, are (b) highly experienced in the management and litigation of class actions and complex litigation in general; (c) have extensive knowledge of the applicable law; and (d) possess the resources to commit to the vigorous prosecution of this action on behalf of the proposed class. Accordingly, Plaintiffs satisfy the adequacy of representation requirements of Rule 23(a)(4).

178. In addition, this action meets the requirements of Rule 23(b)(2). Syngenta has acted or refused to act on grounds generally applicable to Plaintiffs and other members of the proposed class, making final injunctive or corresponding declaratory relief with respect to the proposed class appropriate.

179. This action also meets the requirements of Rule 23(b)(3). Common questions of law or fact, including those set forth above, exist as to the claims of all members of the proposed class and predominate over questions affecting only

individual class members, and a class action is superior - if not the only method - for the fair and efficient adjudication of this controversy.

180. Class treatment will permit large numbers of corn farmers similarly situated to prosecute their respective claims in a single forum simultaneously, efficiently, and without the unnecessary duplication of evidence, effort, and expense that numerous individual actions would produce.

181. This action is manageable as a class action. Notice may be provided to members of the proposed class by first-class mail and through the alternative means, including publication. Further, the claims set forth below based on federal law will apply evenly to all proposed class members. Thus, the superiority and manageability requirements of Rule 23(b)(3) are satisfied.

PRAYER FOR RELIEF

WHEREFORE, PREMISES CONSIDERED, Plaintiffs pray they have of and recover from the Defendants, jointly and severally, compensatory and punitive damages, together with appropriate equitable relief, as follows:

A. Entry of preliminary and permanent injunctions providing that Syngenta shall be enjoined from selling, marketing, distributing, or otherwise disseminating VIPTERA corn and DURACADE corn, in addition to any other product featuring MIR162 until such time as MIR162 has been approved for import to China;

B. Entry of judgment ordering Syngenta to take affirmative steps to remediate the contamination that it has already caused;

C. Entry of judgment finding:

i. Syngenta falsely advertised VIPTERA corn under § 43(a) of the Lanham Act, 15 U.S.C. § 1125(a).

ii. Syngenta's release of VIPTERA corn constitutes a public nuisance;

iii. Syngenta's release of VIPTERA corn was negligent;

iv. Syngenta is strictly liable for damages done by the release of VIPTERA corn;

v. Syngenta release of VIPTERA corn constitutes tortious interference; and

D. Monetary damages including compensatory relief to which Plaintiffs are entitled and will be entitled at the time of trial, in an amount exceeding \$75,000;

E. Prejudgment interest;

F. The costs of this action;

G. Attorneys' fees; and

H. Such other and legal and proper relief.

DEMAND FOR JURY TRIAL

Plaintiffs demand a trial by jury on all issues.

Respectfully submitted,

/s/ Brian L. Kinsley
Brian L. Kinsley
Attorney for Plaintiffs
NC State Bar No. 38683
CRUMLEY ROBERTS
2400 Freeman Mill Rd.
Greensboro, NC 27406
(336) – 333-9899 – Phone
(336) 333-9894 – Facsimile
blkinsley@crumleyroberts.com

/s/ Francois M. Blaudeau
Francois M. Blaudeau
Southern Institute for Medical & Legal
Affairs
2224 1st Avenue North
Birmingham, Alabama 35203
(205) 326-3336
francois@southernmedlaw.com

Pro Hac Vice Pending

/s/ W. Lewis Garrison, Jr.
W. Lewis Garrison, Jr.
William L. Bross
Taylor C. Bartlett
Mark R. Ekonen
Heninger Garrison Davis, LLC
2224 1st Avenue North
Birmingham, AL 35203

(205) 326-3336

wlgarrison@hgdlawfirm.com

william@hgdlawfirm.com

mark@hgdlawfirm.com

Pro Hac Vice Pending

CIVIL COVER SHEET

The JS 44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. (SEE INSTRUCTIONS ON NEXT PAGE OF THIS FORM.)

I. (a) PLAINTIFFS

Richard Frederick Lanier
William Council Lanier
Richard Ralph Lanier, Jr.

(b) County of Residence of First Listed Plaintiff Duplin
(EXCEPT IN U.S. PLAINTIFF CASES)

(c) Attorneys (Firm Name, Address, and Telephone Number)

Brian L. Kinsley, Crumley Roberts
2400 Freeman Mill Road, Greensboro, NC 27406
(336) 333-9899

DEFENDANTS

Syngenta AG, Syngenta Crop Protection AG, Syngenta Corporation,
Syngenta Seeds, Inc.

County of Residence of First Listed Defendant
(IN U.S. PLAINTIFF CASES ONLY)

NOTE: IN LAND CONDEMNATION CASES, USE THE LOCATION OF
THE TRACT OF LAND INVOLVED.

Attorneys (If Known)

II. BASIS OF JURISDICTION (Place an "X" in One Box Only)

- ☐ 1 U.S. Government Plaintiff
- ☐ 2 U.S. Government Defendant
- ☐ 3 Federal Question (U.S. Government Not a Party)
- ☒ 4 Diversity (Indicate Citizenship of Parties in Item III)

III. CITIZENSHIP OF PRINCIPAL PARTIES (Place an "X" in One Box for Plaintiff and One Box for Defendant)

- | | PTF | DEF | | PTF | DEF |
|---|---------------------------------------|----------------------------|---|----------------------------|---------------------------------------|
| Citizen of This State | <input checked="" type="checkbox"/> 1 | <input type="checkbox"/> 1 | Incorporated or Principal Place of Business In This State | <input type="checkbox"/> 4 | <input type="checkbox"/> 4 |
| Citizen of Another State | <input type="checkbox"/> 2 | <input type="checkbox"/> 2 | Incorporated and Principal Place of Business In Another State | <input type="checkbox"/> 5 | <input checked="" type="checkbox"/> 5 |
| Citizen or Subject of a Foreign Country | <input type="checkbox"/> 3 | <input type="checkbox"/> 3 | Foreign Nation | <input type="checkbox"/> 6 | <input type="checkbox"/> 6 |

IV. NATURE OF SUIT (Place an "X" in One Box Only)

| CONTRACT | TORTS | FORFEITURE/PENALTY | BANKRUPTCY | OTHER STATUTES | |
|---|--|--|---|---|---|
| <input type="checkbox"/> 110 Insurance <input type="checkbox"/> 120 Marine <input type="checkbox"/> 130 Miller Act <input type="checkbox"/> 140 Negotiable Instrument <input type="checkbox"/> 150 Recovery of Overpayment & Enforcement of Judgment <input type="checkbox"/> 151 Medicare Act <input type="checkbox"/> 152 Recovery of Defaulted Student Loans (Excludes Veterans) <input type="checkbox"/> 153 Recovery of Overpayment of Veteran's Benefits <input type="checkbox"/> 160 Stockholders' Suits <input type="checkbox"/> 190 Other Contract <input type="checkbox"/> 195 Contract Product Liability <input type="checkbox"/> 196 Franchise | PERSONAL INJURY <input type="checkbox"/> 310 Airplane <input type="checkbox"/> 315 Airplane Product Liability <input type="checkbox"/> 320 Assault, Libel & Slander <input type="checkbox"/> 330 Federal Employers' Liability <input type="checkbox"/> 340 Marine <input type="checkbox"/> 345 Marine Product Liability <input type="checkbox"/> 350 Motor Vehicle <input type="checkbox"/> 355 Motor Vehicle Product Liability <input type="checkbox"/> 360 Other Personal Injury <input type="checkbox"/> 362 Personal Injury - Medical Malpractice | PERSONAL INJURY <input type="checkbox"/> 365 Personal Injury - Product Liability <input type="checkbox"/> 367 Health Care/Pharmaceutical Personal Injury Product Liability <input type="checkbox"/> 368 Asbestos Personal Injury Product Liability PERSONAL PROPERTY <input type="checkbox"/> 370 Other Fraud <input type="checkbox"/> 371 Truth in Lending <input type="checkbox"/> 380 Other Personal Property Damage <input type="checkbox"/> 385 Property Damage Product Liability | <input type="checkbox"/> 625 Drug Related Seizure of Property 21 USC 881 <input type="checkbox"/> 690 Other LABOR <input type="checkbox"/> 710 Fair Labor Standards Act <input type="checkbox"/> 720 Labor/Management Relations <input type="checkbox"/> 740 Railway Labor Act <input type="checkbox"/> 751 Family and Medical Leave Act <input type="checkbox"/> 790 Other Labor Litigation <input type="checkbox"/> 791 Employee Retirement Income Security Act IMMIGRATION <input type="checkbox"/> 462 Naturalization Application <input type="checkbox"/> 465 Other Immigration Actions | <input type="checkbox"/> 422 Appeal 28 USC 158 <input type="checkbox"/> 423 Withdrawal 28 USC 157 PROPERTY RIGHTS <input type="checkbox"/> 820 Copyrights <input type="checkbox"/> 830 Patent <input type="checkbox"/> 840 Trademark SOCIAL SECURITY <input type="checkbox"/> 861 HIA (1395ff) <input type="checkbox"/> 862 Black Lung (923) <input type="checkbox"/> 863 DIWC/DIWW (405(g)) <input type="checkbox"/> 864 SSID Title XVI <input type="checkbox"/> 865 RSI (405(g)) FEDERAL TAX SUITS <input type="checkbox"/> 870 Taxes (U.S. Plaintiff or Defendant) <input type="checkbox"/> 871 IRS—Third Party 26 USC 7609 | <input type="checkbox"/> 375 False Claims Act <input type="checkbox"/> 400 State Reapportionment <input type="checkbox"/> 410 Antitrust <input type="checkbox"/> 430 Banks and Banking <input type="checkbox"/> 450 Commerce <input type="checkbox"/> 460 Deportation <input type="checkbox"/> 470 Racketeer Influenced and Corrupt Organizations <input type="checkbox"/> 480 Consumer Credit <input type="checkbox"/> 490 Cable/Sat TV <input type="checkbox"/> 850 Securities/Commodities/Exchange <input type="checkbox"/> 890 Other Statutory Actions <input checked="" type="checkbox"/> 891 Agricultural Acts <input type="checkbox"/> 893 Environmental Matters <input type="checkbox"/> 895 Freedom of Information Act <input type="checkbox"/> 896 Arbitration <input type="checkbox"/> 899 Administrative Procedure Act/Review or Appeal of Agency Decision <input type="checkbox"/> 950 Constitutionality of State Statutes |

V. ORIGIN (Place an "X" in One Box Only)

- ☒ 1 Original Proceeding
- ☐ 2 Removed from State Court
- ☐ 3 Remanded from Appellate Court
- ☐ 4 Reinstated or Reopened
- ☐ 5 Transferred from Another District (specify)
- ☐ 6 Multidistrict Litigation

VI. CAUSE OF ACTION

Cite the U.S. Civil Statute under which you are filing (Do not cite jurisdictional statutes unless diversity):
28 U.S.C. 1331 and 1332 and supplemental jurisdiction pursuant to 28 U.S.C. 1367 (a)

Brief description of cause:
Class Action for Damages by North Carolina Farmers

VII. REQUESTED IN COMPLAINT:

☒ CHECK IF THIS IS A CLASS ACTION UNDER RULE 23, F.R.Cv.P.

DEMAND \$

CHECK YES only if demanded in complaint:
JURY DEMAND: ☒ Yes ☐ No

VIII. RELATED CASE(S) IF ANY

(See instructions):

JUDGE

DOCKET NUMBER

DATE 11/11/2014

SIGNATURE OF ATTORNEY OF RECORD
/s/ Brian L. Kinsley

FOR OFFICE USE ONLY

EXHIBIT A

Syngenta AG ADR SYT
Q1 2012 Earnings Call Transcript

Executives

- Jennifer Gough : IR
- John Ramsay : CFO
- Michael Mack : CEO

Analysts

- Stacie Shoran : Liberum
- Andrew Benson : Citigroup
- Richard Logan : Goldman Sachs
- Lucy Watson : Jefferies
- Andrew Stott : Bank of America Merrill Lynch
- Amy Walker : Morgan Stanley
- Jean de Watteville : Nomura
- Thomas Gilbert : UBS
- Patrick Jousseau : Societe Generale

Transcript Call Date 04/18/2012

Operator: Good morning, ladies and gentlemen and welcome to the Syngenta Q1 2012 Trading Statement Conference Call. At this time, all participants are in a listen-only mode until we conduct a question-and-answer session and instructions will be given at that time. I would just like to remind you that this conference call is being recorded.

I would now like to hand over to the Chair person, Jennifer Gough. Please go ahead with your meeting and I'll be standing by.

Jennifer Gough - IR: Good morning, and welcome to the call. Today's call is hosted by Mike Mack, CEO and John Ramsay, CFO. Slides to accompany the presentation are available on our website syngenta.com.

Let me, first of all, remind you of our usual cautionary statement. This presentation contains forward-looking statements, which can be identified by terminology such as 'expect', 'would', 'will', and similar expressions. Such statements may be subject to risks and uncertainties that could cause actual results to differ materially from these statements. We refer you to Syngenta's publicly available filings with the U.S. SEC for information about these and other risks.

With that, I would like to hand you over to Mike, who will start the presentation on Slide 3.

Michael Mack - CEO: Thank you, Jennifer. Good morning, ladies and gentlemen. When we last spoke in February, we reported on a year of significant growth, which of course set the bar high for 2012. I am pleased to report that we've made a strong start now to the Northern Hemisphere season with double-digit growth in both North America as well as Europe.

Overall, sales were up by 9% at constant exchange rates with volume up 5% and

price up 4%. Prices were up by 7% in seeds and by 4% in crop protection. Now, the crop protection increase is compared with the first quarter of 2011, which was before we set our mid-year price increases. We're on track though to realize the expected price gain of 2% to 3% for the full year which is, of course, a consequence of the determined action we took last year and the substantial value which our products continue to offer to growers.

In seeds, growth reflects our global presence and the success of our technology, notably, in corn and sunflower. For this business, particularly, the early gains from our integrated strategy are apparent as increased marketing resources are leveraging our sales in areas such as Latin America and Eastern Europe.

Please turn now to Slide 4, which shows integrated crop protection and seed sales by region. Starting with North America, where sales were up 13%. Warm weather there has encouraged an early start to the season and corn planting intentions are at the record level of almost 96 million acres. Planting is just getting underway and customers have been gearing up for buoyant season including for crop protection.

Our business has benefited from increased awareness of both weed and insect resistance issues, which demand adapted solutions combining several technologies. Although fungicides are applied later in the season, the signs are that the rate of adoption is going to increase again.

In Europe, Africa, and Middle East sales were up by 14% and as last year we're seeing substantial growth in developed as well as emerging markets. Part of this stems from the impact of very low temperatures in February and early March, which resulted in winterkill and more than 7 million hectares which is more than 10% of the total, mainly in Northern and Eastern Europe. This has led to a rush to plant spring crops not just cereals, but also corn and sunflower and our broad portfolio has meant that we're well placed to respond to this development. The areas which made the largest contribution for growth were France and Eastern Europe. In France, as we mentioned in February, a change in the law on credit terms moved sales from morte saison in the fourth quarter into the first quarter.

We also saw good underlying growth particularly for CALLISTO on corn in the fungicides. In Eastern Europe, we saw rapid expansion in sunflower and corn and the benefits of a broadened crop protection range.

In Latin America, where the season now draws to a close in the first quarter, sales were lower as draught in Argentina and Southern Brazil affected crop protection usage. Now, this was partly offset by a strong second corn season in Brazil, leading to dramatic growth in our corn seed sales augmented by our enhanced trait and germplasm portfolio.

Overall, we had an excellent season in Latin America with full year 2011 sales up by 19%. Finally, in Asia Pacific sales were up by 2% with performance impacted by cold wet weather in Australia not something we usually get to talk about.

This is however, expected to favor crop development there for the remainder of the year. Sales were also affected by the phasing out of older products in India and

Japan. However, we're seeing continued strong growth in China and in Asian countries.

Let me now hand you over to John, who will continue with some more detail on sales by product line. John.

John Ramsay - CFO: Well, thank you Mike. Please turn to Slide 5, let me first of all draw your attention to one change in the way we are presenting product line sales. Meeting accordance with the new reporting structure we announced in February.

The crop protection product lines no longer show professional products, which are now included in our global lawn and garden business segment, and the same applies to flowers which were formerly reported under seeds.

Turning now to the figures, total crop protection sales were up 9% with constant exchange rates, the main driver for growth came from selective herbicides reflecting strong demand for corn in the U.S. and Europe. In cereals AXIAL, now in its seventh year saw sales up by a third.

Non-selective sales were lower with a decline in GRAMOXONE mainly due to the delayed sales pending introduction of a new formulation in Korea and this was partly offset by growth in TOUCHDOWN across the Americas.

Fungicides saw strong early demand in Northern Europe as well as France. In addition, AMISTAR expanded rapidly in Asia and then in U.S. sales were up by almost 40%. Growth in insecticides reflected the further success of ACTARA particularly on sugarcane in Brazil, the rollout of DURIVO and significant expansion in sales of force for corn rootworm control.

Seed care had a very good start to the year following on from the growth of 18% in 2011. Sales were up strongly in all regions driven by the ongoing success of CRUISER.

Slide 6 shows the sales of new products, which were up 35% in the quarter, with a five-year compound average growth rate of the 39%. Then the market site AVICTA has now been successfully launched on corn and soybean in Latin America. I have already mentioned AXIAL where growth was driven by Europe and by a recovery in Canada after two years of lost cereal acreage.

The DURIVO family of products continues to expand rapidly on rice and vegetables in Asia and REVUS for vegetable, potatoes and blight made a significant contribution to fungicide growth in Europe.

The two newest introductions are SEGURIS for disease control in cereals and the seed treatment VIBRANCE, which will start to make a visible contribution from the second half of this year. Altogether these products which for the full year 2011 had combined sales of \$619 million of peak sales potential of around \$1.8 billion. Turning now to seed sales by product line on Slide 7.

Corn soybean sales were up 13% driven by strong corn demand in all regions and by the ongoing reinforcement of our competitive position through trait introductions and

germplasm enhancement underlying growth in corn was partly offset by lower licensing income, \$30 million less than in the first quarter of 2011 when we received an introductory milestone payment from pioneer. I will say more in a moment about the success of our corn technology.

Soybean sales were lower owing to the reduced acreage expectation in the U.S. and to the ongoing transition of a portfolio to Roundup Ready 2 technology. Diverse field crops continued a growth record for which I'll show you more detail in a moment. Vegetable sales were lower as consumers in Europe and North America rein back expenditure.

Let me now highlight for you some aspects of our global technology advance in corn and please turn to Slide 8. While the U.S. has been at the forefront of our technology development, it is now expanding rapidly in the rest of the world, with nearly 50% of Q1 corn seed sales outside the U.S.

In the U.S. around 85% of the portfolio is now triple or multi stock. We expect sales of VIPTERA this year to be between 25% and 30% of the total. While VIPTERA is our first truly distinctive insect trade Enogen further demonstrates our biotech innovation capacity. It contains the industry's first output trait for corn, one which can significantly improve the profitability of ethanol plants, which use the dry grind method. Launched at the end of last season, this year Enogen will be grown in a closed-looped system on more than 20,000 acres and discussions are ongoing with a number of dry grind ethanol plants.

To give you an idea of the market potential, just under 40% of U.S. corn is expected to be used for ethanol this year. Of this around 90% will be processed by dry grind plants, that is equivalent to nearly 35 million acres.

Latin America is now playing a key role in a corn seed expansion. Around 20% of the portfolio for the 2011 12th season was double or triple stack and this is expected to increase rapidly.

In March, we received approval for our quadruple stack corn in Argentina, which will provide industry-leading control of both above and below the ground insects. In Asia Pacific, our corn sales more than doubled in the first quarter and there is further significant growth potential with the plant launch of triple stacks in the Philippines and corn borer control with herbicide tolerance in Vietnam.

Finally, in Europe sales were up 56% in the quarter with particularly strong growth in Eastern Europe. Of course, GM technology currently plays no role here, but rather we have seen the benefit of our integrated approach as we build further on a strong crop protection presence.

Continuing on Slide 9, our integrated portfolio means that we are uniquely placed to help grow and manage the increasing challenges of wheat and insect resistance. There are now 11 resistant wheat species in the U.S. and 10 million corn acres are affected. This is also a growing problem in Brazil. Our leading corn herbicide portfolio including glyphosate mixtures enable growers to deal effectively with weeds, which if untreated can cause substantial crop loss.

For insect control, we supply combination of chemicals and seed treatment as a complement to our traits package which this year includes our first refuge reduction sales. The range includes our leading soil insecticides force which we have always recommended areas of severe rootworm pressure and which now provides an additional tool to combat resistance.

As you can see from the chart, this is generating strong growth in sales, particularly in the U.S. but also in Europe, notably Hungary where corn rootworm pressure is increasing. Slide 10 shows you the accelerating growth in our Diverse Field Crops, the main driver has been a world-leading sunflower portfolio, which is enabling growers to meet increasing demand for high-quality healthy oils and to show you particularly the rapid growth in Eastern Europe.

Sugar beet showed growth across all regions in the first quarter, with the largest contribution coming from the success of glyphosate tolerant varieties in the U.S.

With that let me hand you back to Mike for some final comments.

Michael Mack - CEO: Thank you John. Turning now to the outlook for the remainder of the year on Slide 11. While weather will as ever play a role, the Northern Hemisphere season is developing well which leads us to expect continued positive sales momentum. Acceleration of integrated benefits should contribute to the achievement of our goal of market outperformance. Price increases and cost savings are on track and together should more than offset currency and raw material headwinds. Our estimate for these remains unchanged at \$300 million and \$350 million. We expect top line growth, ongoing portfolio enhancement and operational efficiency to enable an increase in profitability at constant exchange rates. Strong cash generation will continue and we plan to return around \$1 billion to shareholders through the dividend to be paid later this month as well as a \$200 million share buyback.

As an indication of the strength of our balance sheet in March we made a \$750 million debut bond issue in the U.S. and achieved the lowest coupons ever by a non-U.S. company within our rating category.

A crop based approach is inherent to our integrated strategy and we're keen to update you on the progress we're making. Slide 12 is a reminder of our program of crop based communications which follows on from last year's capital market stays.

The first event is a webcast on May 11, covering our cereals and corn business to be followed then by field trip in September for rise in vegetables. I hope as many of you as possible will join us for these events, but in the meantime, let me open up the call now for questions on the quarter. Nicole?

Transcript Call Date 04/18/2012

Operator: Andrew Benson, Citigroup.

Andrew Benson - Citigroup: Could you give us idea of your view of your market share in the seeds in North America and how the VIPTERA price is developing now, how you see that developing in the medium term as well? Can you talk a little bit

about the seed treatment, what's happening there? Is there something special going on? 24% seems quite high. The non-selectives, you talked about a one-off change in technology whether that was going to make much of a difference as well, if you could just give us an idea there please? Then can you give us a sense of the margin expansion that you hope to achieve this year?

John Ramsay - CFO: Right, good morning Andrew. Can you clarify your non-selective question?

Andrew Benson - Citigroup: You said non-selectives were lower because there was a – that you're going to introduce a new GRAMOXONE or something like that?

John Ramsay - CFO: Okay, yeah, I understand. Look, first on the market share question for corn, look, we've always been, I think, properly circumspect about that at the end of the first quarter. The season itself is the best time and when we talk again at the H1 to get a sense for that. I mean today, for example, corn acre is expected to be just below 96 million, but there is a lot to be planted, and I couldn't even guess the outcome if I don't know what divides the number of acres, we're dividing it into. As our corn seed sales around the world are up 21%, I think that's very representative of the success we're now beginning to enjoy from these investments that we made over the year. So, I wouldn't guess on the specific market share for corn beyond to say that the evolution of the portfolio has gone according to plan. We're pleased with where things are. Your second question has to do with VIPTERA, of course, it's getting a lot of very favorable reviews by farmers. The quality of this trade, the efficacy of the trade is terrific, and we're seeing some of that, of course, reflected in the performance of it down in Brazil and in Argentina where it is increasingly going to be a must have trait. As John mentioned, it's only – it's just now still only 25% to 30% of the offer but we expect that to grow. Again, the receptivity of is quite good. seed treatment this past year, as you know, sales up on the full year basis and this business is now worth more than \$1 billion for the first time. John any more color on the specifics of the seed treatment mix?

Michael Mack - CEO: It is an impressive performance because it comes on top of 18% growth worldwide last year. I mean it is driven by Cruiser, but not exclusively so. But it represents the trend to move to higher value seeds. So we are expanding something like 40% in Europe. It's up about 70% in Latin America which indicates the requirement to protect high-value seeds as you see the valued seeds expanding there. But it also up 20% in Asia. So it is this technology advance which is driving a very high-valued product which gives enormous build advantage to growers. Under GRAMOXONE, Andrew, it's a pretty straightforward answer. We are cutting over to a completely different formulation there and the new formulation has not yet been approved by the Korean authorities. So we are ready to go just as soon as they are and I regard this as – well, it did affect our sales but there is nothing particularly tricky about what's going on behind the scenes on that. Finally John, some color on the margin expansion beyond to say that we are not giving full year guidance on that but ...

John Ramsay - CFO: The EBITDA margin expect. We do expect to enhance the

EBITDA margin in constant currencies. It will very much depend on the top line growth and of course the currency in a margin level is going to be a headwind but on top of the constant currency growth in margin we made in 2011 we expect to make significant growth in 2012 on a constant currency basis.

Operator: Jean de Watteville, Nomura.

Jean de Watteville - Nomura: Three questions on Asia, if I can. First one is on you mentioned the impact of product rationalization for your Asian sales. Can you just quantify in terms of full year sales what would be the impact of the product that you discontinue? Second question, you mentioned strong sales of AMISTAR in Asia, now we all know that your sales of AMISTAR in Asia were historically very limited and so a big part of the (Growstar if) AMISTAR going forward is in Asia. Can you just develop on what phase you are of the development of AMISTAR in Asia. If you can just highlight what's the patent protection and probably share with us a couple of sales targets of what you think you can achieve in Asia with AMISTAR? Lastly on GRAMOXONE, now I understand most of your sales of GRAMOXONE are in Asia and particularly in China. My understanding is that there are some discussions of a ban of some formulations of GRAMOXONE. Can you tell us what are your sales of GRAMOXONE in Asia and what could be the potential impact if any then happens in China of GRAMOXONE?

John Ramsay - CFO: Three questions, look I think on the first one, the product rationalization this is and has been an ongoing journey for the Company over the past 12 years, we've done it before, we'll continue to do it, we're undertaking now our small products very limited impact and of course as our new products continue to evolve as a percentage of the total portfolio some of the other ones naturally just get smaller and it makes good sense to begin to emerge away from those. So there is nothing -- it's not a new development and there is nothing of particular significance to it. The second one on AMISTAR in Asia Pacific you're right to point out that it continues to grow nicely. It has terrific efficacy on important Asian crops, the AMISTAR works on rice, AMISTAR works on vegetables and as you know, well from the U.S. experience it works on corn and it works on the cereals. So, all of the things that the Asians are undertaking to make their crops more productive AMISTAR has a market therefore, U.S. specifically about the sales targets, I mean, and I'm not trying to get around the question, but over the years we have been always more wrong than right about the potential success of AMISTAR, it has gone from strength-to-strength and the capacity expansions that we put in place have just a testimony to the power of this active ingredient to just continue to be a blockbuster that surprises. So, I mean if I were to give you a sales target today, my answer is, we would go past it, it's big part of the range and it is going to continue to be part of the story there. Finally, on remarks, I mean you're right to say that the Chinese today are undertaking an assessment of the various forms of GRAMOXONE a form being a straight product, a dilutive product and they're talking about a gel formulation two things about that. First, we are working very closely with them on a technical level and then the regulatory area and so we regard that as very much a local supplier in that respect. So nothing will come as a surprise to us, one. The second thing is to the extent that anything has changed it is expected that the phasing period would be a period of years for us of course and our

competitors in China to be able to adopt to the new form. So as we hit here today, I see no significant potential for any change in the regulatory status of this to be a financial surprise to the firm and we will have plenty of visibility on it if and as it gets decided.

Jean de Watteville - Nomura: Just the patent protection if I missed that in Asia?

Michael Mack - CEO: I am sorry.

Jean de Watteville - Nomura: Just I was wondering about the timing of the patent protection if I missed that in Asia on the main countries.

Michael Mack - CEO: We have got some years to run here and it's different years by different products. Any specific country you were interested in?

Jean de Watteville - Nomura: Malaysia I think is one of the important growth potential, Indonesia or Southeast Asia in general are we talking about mid-10 or I know the decade, we know it's off-patent in Brazil already. It is getting off-patent in North America. So I am just pretty curious what's the kind of timeframe of the patent protection you have in the main countries in Asia.

Michael Mack - CEO: Sure. Look, first, of course Jennifer can get back to you with the schedule, John, on virtually all of the countries, but I think the important point here is the way we have been thinking about this product as it goes off patent has been well established and I think our track record speaks for itself which is that we've taken a lot of these big markets to mixtures, have supplied some of the generic demand for this already, and the growth of the underlying growth of demand for this product is the same that continues to be the most significant feature of the story and if and as these things come off patent that is not something that's keeping us awake in night.

Operator: Patrick Jousseume, Societe Generale.

Patrick Jousseume - Societe Generale: Congrats on this good start. Two questions on actually corn, North American corn. Can you quantify little bit the royalty income that you got in Q1 and in 2012 what you expect on your corn portfolio? Second question, I did realize the corn season has started pretty early and do you expect a big impact on your corn protection portfolio is and maybe you can comment on that the maturity where that's been chosen is likely to be longer than last year, the corn maturity?

Michael Mack - CEO: Yeah, let me address the first question, the second question first, it is true that sometimes in early season can give us difficulty in the crop protection business if it becomes more immediately after it's wet and from a technical point of view farmers can't physically get into their field to spray a pre-emergent selective herbicides that can be a problem. That wasn't the case this year, it got rather warm sooner, it was dry enough and the crop protection business is off to a great start and so there is nothing about the earliness of the season that is in and up itself going to have an impact of what is happening here of course is as farmers have an early season they are looking forward to a good season and because they are going to probably have rather full amount of time to grow their

crop, that means that they're going to put as much investment in it as they possibly can, which is why today we're giving you a sense of the confidence that the Northern Hemisphere season getting off to a great start. John, on the first question?

John Ramsay - CFO: On the royalty Patrick, the difference in royalty in the first quarter is about \$30 million and that does relate to corn as specifically our rich one corn license income, but look that the thing about the royalty income is always going to be a bit lumpy particular between quarters as the income is dependent on certain hurdles and different ways of contracts are constructed and anticipate for the full year taking our whole royalty income in total and we should end the year with a level of royalty income roughly in line with last year, and therefore that's the \$30 million difference will be made up as we get into the seeds and we get royalty income from other streams.

Patrick Jousseume - Societe Generale: Just to come back on the corn. Did you see in your corn seeds portfolio longer maturity corns? Or has it shifted this year?

John Ramsay - CFO: I think by virtue of it being a bit early that would directionally say that there will be more longer maturities planted to the extent that they're available, but the season is getting underway right now, and there is a number of weeks to run and I wouldn't want to make a comment about what the rest of the competition has to offer in the way of short, I mean mid versus longer maturities, but our farmers are eager to get in their field and it's underway as we speak, but so far it's looking quite positive.

Operator: (Stacie Shoran, Liberum).

Stacie Shoran - Liberum: Just one question really. Your Latin American corn and soy seed business, very strong growth. You are talking about market share gain. I just wondered whether you could give us a bit of an update on your market share in these regions, what's driving the share gains? It's quite a small business today, but what are your expectations for that business over the next few years?

John Ramsay - CFO: The Latin American business is a bit of a version of my answer around AMISTAR which is it's a region that continues to – that we set high goals for ourselves and fortunately we've been able to even exceed those over these past years. Like some of the strength of the portfolio and crop protection and the strength of our go-to-market strategy there is now enabling us to take full advantage of some of the technology that's been adopted in the corn seed business as well as soybean seeds. Of course, the seed treatment offer that we have there all of these things come together really nicely in some of this big acre crops. We mentioned I think at the Capital Markets Day, I know we mentioned at the Capital Markets Day the tremendous potential we have in the sugarcane to ethanol business, for example, where (Plenus) is truly an innovative offer. All of the crop protection chemicals that we have in sugarcane continue to grow, but there is also coffee, there is plantation, Brazil continues to just develop the quality of its agriculture business. You weren't just talking about Brazil, but you're also talking about the rest of Latin America, including Argentina, and it's been very encouraging to us. I think right now we estimate that our market share of 14% in corn and that's up substantially from single digits just a few years ago Argentina we think it's about

17%, which is also up substantially, and it's again driven on the back of technology as well as, frankly, the breadth of the service offer that we have to the customers.

Stacie Shoran - Liberum: Just a follow-on, I mean, just on the corn and soy seed in particular, and is there anything that is driving those market share gains that you've reported today?

Michael Mack - CEO: I think what John said was that the Q1 sales in LatAm reflected a really strong second season for corn. Second season for corn is the (sofrina) season in Brazil and main season in Argentina. We believe that we've had share gain in both of those markets. John, the corn seed sales percentage change there is what year-on-year?

John Ramsay - CFO: Yeah Sophie, I mean just to say, in Latin America, just to make clear we're not selling soybean at this time of year. That comes in third and fourth quarter, but sales for corn in Latin America for the total region are up 76%. While it's early days, those estimates that Mike has given for market share look achievable on that basis. So, that's a really significant advance and thus our technology is going in there which is clear, but also I think we're probably getting some leverage on our new strategy of going to market on a combined basis, but the number is 76% growth.

Operator: Andrew Stott, Bank of America Merrill Lynch.

Andrew Stott - Bank of America Merrill Lynch: Just a question on the integration program, where you are now, which geographies you still got to do? I think if I remember, I think you're saying mid this year the whole thing should be done, so sort of a qualitative update there. Maybe question for John specifically. I wonder if you could isolate that GRAMOXONE impacting Korea for Q1 if that's possible. Then final question is VIPTERA, I think you've gone from and correct me if I'm wrong, 20% of the portfolio in U.S. corn to – I think you said 25% to 30% is a range year-on-year. So, my question is the base right, is my 20% right? Then second question related to VIPTERA is what is the potential here? Is there a target that you can share with us for the mid-term?

Michael Mack - CEO: Andrew, look, the first thing on the integration, yes, it's going nicely. We've already integrated 16 of 19 territories, which means that we have three left. We believe those will be completed by mid-year. Just in the way of background on this, it's not that there is anything in the way, but here in Europe we're having to work closely with the workers councils and to be sure that we do it in conjunction with the agreements that we have in place with our employees. So, but the employees and the management, everybody is terrifically enthused by getting underway with this and so there is nothing of significance standing in the way of achieving that plan. On VIPTERA before I turn it back to John, on your second question, VIPTERA we think it has broad addressability on some 50% of the corn acres. And, of course, you know that some of the underlying insect pressure, whether it's corn or European corn borer – a corn rootworm or European corn borer or some of these lepidopteran pest, it can change from year-to-year. The amount of pressure can change from year-to-year, and the entire (dice borer) itself can move. So, 50% is a pretty good number, which is to say that we've got some room yet to

run on the evolution of VIPTERA within this, and again, it is getting great receptively in the market. John, on GRAMOXONE.

John Ramsay - CFO: Yeah. The GRAMOXONE phase is a phasing issue associated with bringing in the new formulation in Korea and the number will be around \$10 million.

Andrew Stott - Bank of America Merrill Lynch: Can I just follow-up Mike on your comment on the three territories not yet achieved. Is that a modest red flag about the 300 million target for this year or not?

Michael Mack - CEO: No, not at all. Until we have properly finished our discussions with the workers councils, they would regard it as inappropriate for us to say that we have completed it, but everything is going far better than we expected it would on this. Folks are looking forward to getting aligned behind this strategy. Many parts of it, of course, are already working to the new strategy but we just need to complete our work.

Operator: Richard Logan, Goldman Sachs.

Richard Logan - Goldman Sachs: Thanks for taking my questions. Most of them have been answered. But I just wanted to follow-up on the Enogen comment. It sounds like there is quite a large potential growth opportunity there. I wondered if you were able to give any sort of quantification of your expectations (heights) over the next few years in terms of the ramp up there. Then just on the pricing, if you could just confirm on the crop protection pricing, the increase that was achieved in the first quarter year-on-year? Then just on the integration, I mean you said about that you have been pleased with how that process had been going and that it was exceeding our expectations. I mean are you able to give us just some examples of like specific examples of things that have surprised you on the upside and any areas where things haven't gone quite as you expected just to get a bit more color on that, thanks.

Michael Mack - CEO: I'll take the first and the third maybe John you can offer a bit more detail on the crop protection pricing particularly the comps relative to the target we set at the mid year. First on Enogen, I mean what are we doing this year, because it didn't get approved regulatorily until February we were not able to put a lot of these corn into the ground and so what we are going to be able to have available to work with some of these customers on an ethanol plant basis, is a small handful of customers and that's physically what we're going to be able to do. Now, the major priority for us Richard during the year is going to be to sharpen the value proposition. We know that Enogen corn is able to give a range of benefits to these ethanol plants. Operators are able to expand the throughput of the plant. They are able to of course eliminate the use of their liquid emulates but they are also able to reduce some of the temperature, but we got to really sharpen up this value proposition. We believe it may offer \$0.08 to \$0.11 per gallon of benefit, and of course, as a percentage of their existing profit this is quite a good number, but we haven't had enough experience on a range of a number of different plants to be able to want to quantify it. As John said during his remarks, when you think about the corn crop for 40% of it going to ethanol and 90% of that amount being using this

very method of the addressable market is quite big, but I wouldn't want to get in front of ourselves. I'm telling you exactly where that's going to be. Now, that's been deregulated though, I can't promise that as the results of these trials come to pass, we're going to be in a much better position to be very sharp with you on precisely that question. On the integration, we're pleased with where it's going. Any time one imagines getting into reorganizing an entire company, 26,000 employees, you plan for the best but you can't know exactly how that's going to go. It was met with a high degree of enthusiasm. Of course, we spent a lot of time getting ready and planning for this all around the world, but for those of you who went to our Capital Markets Days in London and then in Stanton, Minnesota last year, you've got a sense for that, you ask can I give you a couple of examples of things that are going well. One of the things that we did after the Capital Market Days was we took that same experience, call it, demonstration days and we're doing that experience around the world and all of the territories, and we're inviting of course our employees, but also other stakeholders including customers to these events. Literally thousands of people have gone through the same experience that those of you who attended these events. Of course that's going to help now accelerate the overall understanding across the Company about what we're trying to do here, but it's also giving us an opportunity to have some exposure with customers. Again, the reflection that we're getting back from this is people can see the potential of this strategy to make a difference. You say, what's not going as well as expected, again, overall this thing has gone way better than we thought, I think, but because it's happening so quickly because people are wanting to get very quickly into what are the new ways of working, what you want me to do differently and we're just finding that we're having to pick up the pace in every respect to cut over to the new system. I can assure you that people in the information technology, the IS departments are very busy making sure that everybody gets integrated sales reports. The move to having an integrated offer and being sure that we can fully enable that has got us busy, but it is a good busy, as about all I can say to that. John, on CP pricing.

John Ramsay - CFO: On CP pricing, the figure is up 4% in the quarter as well as the Group number. I mean, clearly, that's a pleasing start opposite our target of 2% to 3% for the full year. The other pleasing aspect of it is that the 4% is made up of contributions from all the regions. So the price increase is widespread across the Group. But we still have a long way to go. We've still got the Latin American season, the mean season ahead of us, although that's looking reasonably positive, given the environment in which we're in, but nevertheless there's a long way to go at this stage, but I would still be at the target of 2% to 3% for the full year.

Operator: Patrick Jousseume, Societe Generale.

Patrick Jousseume - Societe Generale: Following a question on actually soybean seeds in North America. I understand the corn business did pretty well but the soybean must have gone down. Can you quantify a little bit? And I guess it is because of Roundup Ready 2 rollout, but can you be able to put some colors on that?

Michael Mack - CEO: Well, first of all, we can't know how it's going to end. As I

said earlier we are always a bit cautious about saying how things are going to finalize when the season is all over. So I don't know that with precision. Two things about this, first, acres are down Patrick and we believe they are going to be down from every single indication that's the first thing and yet having said that, I noticed just yesterday in some of the media clippings that come through that some farmers are headed over toward the soybean. So, I think we can't really be definitive until the season is over, but it looks to be that soybean as the acres are going to be down, one. Two, yes, we're converting over to Roundup Ready 2 technology and we got that right now in bulk of 30%, 35% of our portfolio and we're converting that as quickly as we can be the option of Roundup Ready 2 technology. Now, this has been my observation of the last two seasons has got off to a bit of a slow start again, not making a comment here opposite the competitors, but it seems to have picked up the pace, but we're licensee of Roundup Ready 2 and we're operating that into our portfolio. So I just regard that as really a phasing matter.

Patrick Jousseume - Societe Generale: And will it impact elsewhere in the world in this technology rollout?

Michael Mack - CEO: The Roundup Ready 2 technology again, I'm not in a position to characterize the big marketing intentions of that, remember (we're) licensees (Indiscernible) for that herbicide technology. It's to best of my understanding that that will be marketed in other places of the world that have soybean to the extent that it is adopted in Brazil for example Syngenta would be a licensee of that in Brazil and we do have a soybean seed business known there and you can see from our soybean overall numbers, we got a very strong offer between the seeds, the crop protection as well as the seed treatment, so. Okay, with the big markets of course, for soybean are North America and LatAm and we intent to be very active in both of those.

Operator: (Lucy Watson, Jefferies).

Lucy Watson - Jefferies: Two questions on VIPTERA, was VIPTERA at 25% to 30% at your corn portfolio. I'm wondering if this penetration is at all impacted by the availability of seeds supply or is it period demand driven metric and as a follow-up to that, can you provide any sort of an update on expected timing for key import approval for VIPTERA? Then one separate question, I believe your press release says corn seeds sales were up 16% in the U.S. in the quarter. I'm just wondering what the breakdown was between pricing volume and what your price outlook would be for seeds for the full year?

Michael Mack - CEO: Fine, I mean on VIPTERA I mean, we've known for a long time Lucy that this was going to have great receptivity, because we were able to see the efficacy of the product more in opposite these broad lap adapter in (pest) pressure and indeed it is really getting a lot of a very favorable reviews by grower. So, that 25% to 30% is a number that is pleasing to us we're selling as much as we have to offer in the portfolio and we'll get that up to that 50% just as quickly as we can. So, I think the demand is driven by the underlying quality of the product to help drive yields and they were getting ready to also get that incorporated into our portfolio to its fullest. On the import approval, it has import approval in all of the

major markets. There isn't outstanding approval for China, which we expect to have quite frankly within the matter of a couple of days. That remains on track for approval to the very best of our ability. Of course, the regulatory authorities are not something that we can handicap definitively, but we know of no issue with that whatsoever, and finally, John on the full year pricing for seeds and the mix effect of that, I mean, how could we best characterize them?

John Ramsay - CFO: The simple answer is the 16% refers to North American corn excluding the royalty effect in terms of growth and price within that is between 5% and 10% and the rest is volume.

Lucy Watson - Jefferies: Did you have an update on your outlook for pricing seeds for the full year?

John Ramsay - CFO: Pricing seeds for the full year, I mean we did see it not too dissimilar from where it is in the first quarter, but it's a long way to go, but I would say not dissimilar from Q1.

Operator: Amy Walker, Morgan Stanley.

Amy Walker - Morgan Stanley: I would like to ask, firstly please, you talk about acreage impacts on soybean seed sales, but Monsanto managed to put through a 12% growth in North American soy seed in its most recent quarter versus your sales being down this quarter, does that mean that you're actually losing share in U.S. soy seeds? The second question is, can you give us a bit of an indication on what you're seeing in your pricing developments sequentially quarter-on-quarter, particularly in crop protection? Given that you are comparative in pricing and costs are going to get tougher through the year, are you expecting to achieve further to control price increase since we're able to achieve the 2% to 3% guidance? Lastly, do you think there is a risk of a pull forward in demand from Q2 into Q1 based on the comments you made about more the non-wet conditions you seen in some regions in this quarter?

Michael Mack - CEO: Yeah, maybe John can help on the quarter-to-quarter comparison for pricing and the first question Amy again, I have to impress upon you, I'm not prepared to call the full season on either corn or soybean until the season is in and planted I can't know what that's going to be and I wouldn't want to comment on Monsanto's results or their outlook on their market share evolution. And it's as much as we are transitioning to Roundup Ready 2 technology and excluding for the acreage impact of soybean, if we end up having some slippage on market share for soybean on account of the transition to new technology that wouldn't be a complete shock to me. So, I'm not here today saying we have a high degree of confidence of market share evolution, but I'm here to say that there is nothing underlying about our soybean offer, our soybean germplasm that gives me any concern. Keep in mind that big thing is that corn is the profit driver here and I think the corn seed sales up 21% versus last year talk to the investments that we made and they are all of the money that we've been spending over these years has been to completely renovate and make unique in many respects of course, this corn offer and I have said now for a number of years, it's portable to other countries and it's portable across other crops and we continue to get all of the evidence that we

need to do that. So, corn is the big profit driver for us here and I don't know what our soybeans are going to land we have to say that it's -- the season is still in front of us. On the pull forward to look know I think the -- what we said on Q1 opposite more seasonal for France as it was more a delay from Q4 into Q1 as opposed to anything being pulled up from Q2 into Q1. So, no there is no to best of our knowledge there is no material impact on the sales momentum of Q1 as being part of -- as it part of Q2. John, again this pricing question...

John Ramsay - CFO: Yeah, that the price evolution, I think we're targeted 2% to 3% for the full year, and you're right to say as we went into the second half of 2011 than we did have and we started to put some price, price increases in place. So, the comparison for the full year will have to take account of that and the absolute magnitude really depends on Latin America are actually on what decisions we make going into the season and we've not yet decided and how that will play out, but at the present time we would see some opportunity for further price increases in Latin America and just given the evidence of the first quarter and the continuing buying conditions with the level of farmer income then that we're experiencing there. I mean taking that all together 2% to 3%, I think is a very solid target.

Operator: Thomas Gilbert, UBS.

Thomas Gilbert - UBS: Just to wrap up two questions (Plenus) in Latin America, can you give us an idea now that the season is trying to close either the absolute size of sales or the growth rate? The second question, again Latin America, could you update us what percentage of barter sales is in Brazil or in fact the entire continent? Can you confirm that the dry weather will not lead to any product being returned to you because your invoice is based on consumption? Maybe the same question to the distributors down there, are they as safe from any profit hits as you are from returned product that has not been sprayed at farm level?

Michael Mack - CEO: Thomas, the first on (Plenus) two things about that. We informed you all last year that this product is very unique. We're putting in place capacity, of course, and we are making the (Plenus) offer, and its acreage potential is vast, which you know and we've already taken in a way forward sales of several \$100 million, where people have expressed a commitment to take their sugarcane plantations to this technology just as soon as we geared up to fully supply it. So, that remains extremely encouraging. Of course, along the way, we're able to significantly expand the sales of our products into sugarcane, whether it would be insecticide or the herbicide. So, that's going quite nicely. John, I think the second question was broadly all around risk and get better management therein.

John Ramsay - CFO: Yeah, absolutely I can tell you what (indiscernible) this is a season where we're very pleased to be on the consumption model, because the momentum coming out of the first part of the season going into the second was strong and then of course, there was the drought, now that probably does need that in Southern Brazil and in places in Latin America there will be some higher inventories at distributors, but not that it affects us and so far as our profit is concerned, because as you see on a consumption basis. As respect of the distributors, I think it will vary as a broad statement the distributors generally get

protected by the principal as a broad statement, although and that may result in some working capital expansion from our competitors et cetera, but distributors tend to be largely protected because of the principal. Coming back to the question of barter, about 40% of our sales are on barter and as you'll find in Brazil, about 60% of our sales are on secured terms, one way or another including barter on credit and barter for cash and indeed our cash sales there at last season increased significantly, just represented actually of the amount of money that's going around in that part of the world in terms of the levels of incomes that farmers are able to command.

Thomas Gilbert - UBS: Just the 40%, John, that was the number for the Continent, that's Brazil overall?

John Ramsay - CFO: That's Brazil. The barter in Argentina is at a similar level, but we're not planning to operate barter in the markets outside of Brazil and Argentina at this time.

Michael Mack - CEO: Ladies and gentlemen, that concludes the call today. Of course, if you have other questions or we weren't able to get you today, I apologize for that. Of course, you can contact Jennifer or (Lars) in Investor Relations, and again hope that some of you would be able to join the May telecast and otherwise look forward to talking with you at the half year in July. Thank you.

Operator: Ladies and gentlemen, thank you for your participation. This concludes today's conference. So, you may now disconnect your lines. Thank you.

© Copyright 2014 Morningstar, Inc.

EXHIBIT B



REQUEST FORM FOR BIOSAFETY CERTIFICATE(S)
ISSUED BY THE CHINESE MINISTRY OF AGRICULTURE

Name of company Transcendental Supply Company ("Recipient")
Address 2803 N. 22nd St.
Decorah, IA 52001-6252
Contact person Minglu Li Title Sales
Business phone 218-53-7747 Business fax 714-990-4490
Email address cli@transcendentalsupply.com

Biosafety Certificates for the following transgenic event(s) were issued to Syngenta Seeds AG, which has since been legally merged into Syngenta Crop Protection AG, by the Ministry of Agriculture (MOA) of the People's Republic of China (PRC).

Corn Product

Bt11 ☐ Bt176 ☐ GA21 ☒ MIR604 ☒ MIR162 ☒ 3272 ☐

Exporting Country

UNITED STATES ☒ ARGENTINA ☐

(Please check the ☐ for exporting Country)

The requested Biosafety Certificates will be provided to Recipient to assist Recipient in obtaining required authorization for shipments containing the above marked Corn Product(s) into China. Recipient hereby acknowledges and agrees as follows:

- The Biosafety Certificates are based on proprietary packages of safety information provided by Syngenta Seeds AG to the Ministry of Agriculture of the PRC and the underlying data was developed and submitted by Syngenta Seeds AG at considerable expense.
- Recipient agrees to use the Biosafety Certificate(s) only for the purpose of obtaining the required authorization(s) to import shipments containing the corresponding above marked Corn Product(s) into China, and not to provide a copy, directly or otherwise, to any third party except majority owned or controlled affiliates of Recipient.
- Recipient will comply with all applicable laws and regulations regarding the transactions or activities for which the Biosafety Certificate(s) is used.
- The Biosafety Certificate(s) provided allows importation of the above marked Corn Product(s) as raw materials for processing for food and feed use only, not for any research purpose or cultivation purpose. Recipient agrees to take reasonable safety control measures to ensure that raw materials of the Corn Product(s) imported will not be released into the environment or used in a way that would cause potential risk to biological diversity, sustainable utilization or human health.
- The Biosafety Certificate(s) may not be used except in accordance with the terms stated herein and any violation of such terms may cause substantial injury to Syngenta Crop Protection AG. Therefore, in addition to any other remedies which would be available, Syngenta Crop Protection AG and/or its affiliates which provided the Biosafety Certificate(s) to the Recipient reserve the right to withdraw the use of the Biosafety Certificate(s) if the Recipient is not in compliance with the terms agreed to in this document.

Acknowledged and agreed by Recipient:

Minglu Li Authorized signature (Legal person)
MINGLU LI Name (in print)
Sales Title
8/13/14 Date

Please complete this Request Form and return to the attention of "Abby Vulcan, Stewardship".

abby.vulcan@syngenta.com
Or
612-656-8564 (Direct)
1-800-858-8664 (Fax)

EXHIBIT C



National Grain and Feed
Association



North American Export
Grain Association

1250 Eye Street, N.W., Suite 1003, Washington, D.C., 20005-3922
NGFA: (202) 289-0873 NAEGA: (202) 682-4030

**Joint Statement
by National Grain and Feed Association (NGFA)
and North American Export Grain Association (NAEGA)
on Media Reports of Lawsuit Involving Syngenta's
Agrisure Viptera™ Biotech Corn (MIR 162)**

August 26, 2011

The National Grain and Feed Association (NGFA) and North American Export Grain Association (NAEGA) today issued the following statement in response to media reports of the lawsuit involving Syngenta's Agrisure Viptera™ biotechnology-enhanced corn (MIR 162), which has received regulatory approval or authorization in the United States and several foreign markets, but not in China.

"The NGFA and NAEGA have been made aware that Syngenta America Inc. has initiated legal action against Bunge North America Inc. in the U.S. District Court for the Northern District of Iowa. Both Bunge North America Inc. and Syngenta are member companies of the NGFA, while Bunge North America is a member of NAEGA. NGFA and NAEGA member companies make independent business decisions with respect to commercialized biotech-enhanced events based upon each company's assessment of the risks and rewards associated with each new event.

"The NGFA and NAEGA both strongly support agricultural biotechnology and other scientific and technological innovations that contribute to the production efficiency and availability of a safe, abundant and high-quality food and feed supply for U.S. and world consumers.

"The grain handling and export industry have communicated consistently, clearly and in good faith with biotechnology providers and seed companies about the importance of biotech-enhanced events in commodity crops receiving regulatory approvals or authorizations – prior to commercialization – in key export markets where foreign governments have functioning regulatory systems that approve biotech-enhanced traits. These communications regarding key export markets, identified through market and trade assessments, have been conveyed through industry trade associations and in direct communications by individual companies.

"Within the U.S. grain and oilseed handling and marketing system, each company makes its own determination as to whether to accept various commodity crops – including those containing biotech-enhanced events – driven by customer preferences, regulatory regimes, contractual

commitments and the respective markets they serve. Given the nature of the U.S. grain marketing system, these business decisions extend to the first point of sale from the producer. The NGFA in the late 1990s developed sample contract clauses that companies could consider using based upon their specific market needs and situations with respect to biotech-enhanced traits. These sample contract clauses were updated most recently in May 2007. NAEGA and NGFA member companies continue to make commercial decisions on appropriate responses to the commercial introduction of new biotech-enhanced events based upon the individual company's facilities, economic considerations and market opportunities.

"Providing all participants in the value chain, from producer to consumer, with the ability to choose is a key driver in enabling coexistence of diverse interests in agriculture in the United States.

"U.S. farmers, as well as the commercial grain handling and export industry, depend heavily upon biotechnology providers voluntarily exercising corporate responsibility in the timing of product launch as part of their product stewardship obligation. Technology providers must provide for two critical elements: First maintaining access to key export markets like China, or for that matter any market like China that has a functional, predictable biotech-approval process in place; and second, proactive transparency to all stakeholders when there is a potential for restricted marketability of their products based upon approval status in major markets. The negative consequences of overly aggressive commercialization of biotech-enhanced events by technology providers are numerous, and include exposing exporting companies to financial losses because of cargo rejection, reducing access to some export markets, and diminishing the United States' reputation as a reliable, often-preferred supplier of grains, oilseeds and grain products. Premature commercialization can reduce significantly U.S. agriculture's contribution to global food security and economic growth.

"Putting the Chinese and other markets at risk with such aggressive commercialization of biotech-enhanced events is not in the best interest of U.S. agriculture or the U.S. economy."

-30-

The NGFA, established in 1896, comprises more than 1,050 member companies that operate more than 7,000 facilities and handle more than 70 percent of the U.S. grain and oilseed crop. The NGFA's membership encompasses all sectors of the industry, including country, terminal and export grain elevators; commercial feed and feed ingredient manufacturers; biofuels producers; cash grain and feed merchants; end-users of grain and grain products, including processors, flour millers, and livestock and poultry integrators; commodity futures brokers and commission merchants; and allied industries. The NGFA also has strategic alliances with NAEGA and Pet Food Institute. In addition, affiliated with the NGFA are 26 state and regional grain and feed trade associations. Canadian and Mexican firms also are NGFA members.

NAEGA, a not-for-profit trade association established in 1912, consists of private and publicly owned companies and farmer-owned cooperatives that are involved in and provide services to the bulk grain and oilseed exporting industry. NAEGA's mission is to promote and sustain the development of commercial export of grain and oilseeds and their primary products. Through a reliance on member action and support, NAEGA acts to accomplish its mission from its office in Washington D.C., and in markets throughout the world.

EXHIBIT D



National Grain and Feed Association

www.ngfa.org

1250 Eye Street, N.W., Suite 1003
Washington, DC 20005-3922

P: (202) 289-0873

F: (202) 289-5388

May 1, 2014

Legal Obligations and Potential Market Impacts Associated with Biotech-Enhanced Seeds Producing Grain Not Approved for Import into U.S. Export Markets¹

Introduction

Syngenta Seeds Inc. has launched a new biotech-enhanced corn seed called Agrisure Duracade™ 5307 for planting in the United States in 2014. As of May 1, 2014, this trait has not been approved for import as food or feed by significant U.S. export markets, including China, the 28 countries of the European Union (EU), Colombia, Switzerland, Brazil, Egypt, India, The Philippines, Indonesia, Thailand, Singapore, the Russian Federation, Kazakhstan, Belarus or Turkey. Like the United States, a number of these countries (including China) have a zero-tolerance policy regarding the presence of unapproved biotech-enhanced traits in imported shipments.

The costly trade disruptions and commodity price impacts that can result were spotlighted when China in mid-November 2013 began rejecting shipments of U.S. corn and distillers dried grains with solubles (DDGS) after detecting the presence of Syngenta Seeds' Agrisure Viptera™ MIR 162, which has not received import approval yet. Some U.S. soybean shipments to China also were effected when trace levels of MIR 162 were detected.

This recent experience demonstrates how access to international markets for U.S. farm products can be disrupted or prevented when biotechnology-enhanced crops are commercialized before regulatory approvals are granted by importing countries.

1. *How much did these export market disruptions with China cost U.S. farmers?*

An analysis completed in early April 2014 by the National Grain and Feed Association (NGFA) estimated that the total economic damage of Syngenta's commercialization of Viptera MIR 162 prior to Chinese import approval – and the trade disruptions that ensued after China detected MIR 162 and rejected shipments under its zero-tolerance policy – ranged from **\$1 billion to \$2.9 billion**. Using a mathematical model that forecasts the

¹ This document is provided for informational purposes only, and does not constitute advice or recommendations to any segment of the corn value chain. While the information is believed to be accurate as of the date of publication, the National Grain and Feed Association makes no guarantees or warranties, expressed or implied, regarding the application or use of the contents. Each member of the value chain needs to make its own marketplace decisions, and nothing in this document should be construed as constituting a recommendation that members of the value chain take joint action of any nature. Further, nothing contained in this publication is intended as legal advice. Competent legal counsel should be consulted on legal issues.

national average corn price based on U.S. corn ending stocks, NGFA estimates that the trade disruption:

- **Depressed U.S. corn prices by 11 cents per bushel.** That amounts to a **\$1.144 billion loss for U.S. corn growers** over the last nine months of the 2013/14 marketing year (December 2013 to August 2014), as the United States in effect was shut out of the Chinese corn market.
- **Depressed U.S. DDGS prices by an estimated \$7 per metric ton,** resulting in a \$202 million loss for this sector during the current marketing year.
- **Depressed U.S. soybean prices by an estimated 15 cents per bushel,** amounting to a \$375 million loss for soybean farmers during the current marketing year.

Importantly, these cost impacts do not reflect likely losses of U.S. corn export sales to China that otherwise could have occurred in 2013/14 were it not for the Viptera MIR 162-related disruption in shipments and sales.

2. *What costs could be borne by U.S. farmers and the grain industry from commercialization of Duracade 5307 since it has not been approved yet in several key U.S. export markets?*

NGFA conducted a second analysis that found the estimated cost of the **disruption to U.S.-China trade alone** resulting from commercialization of this new corn trait could range from **\$1.2 billion to \$3.4 billion (with a mid-point estimate of \$2.3 billion)** for the 2014/15 marketing year. This analysis is predicated upon the belief that enforcement of a zero-tolerance policy by China will prolong the lack of access for U.S. corn to that important market for the duration of the 2014/15 marketing year (which runs from Sept. 1, 2014 to Aug. 30, 2015). China's regulatory process typically takes at least two years to review and approve new biotech-enhanced traits following approval by the United States.

The NGFA analysis assumes the same price-depressing impacts will occur for U.S. corn, soybean and DDGS as determined in the Agrisure Viptera MIR 162 case study. For Duracade 5307, most of the economic loss would be borne by U.S. corn producers (\$1.538 billion), with most of the remainder falling on soybean farmers (\$533 million) and DDGS sellers (\$270 million). These cost impacts were derived after accounting for an estimated \$64.9 million in economic benefits associated with commercialization of Duracade 5307 in terms of increased corn production resulting from improved rootworm control, as well as profits for Syngenta, its seed licensees and seed resellers.

3. *How long did Syngenta wait to obtain Chinese import approval of Duracade 5307 before deciding to sell it for planting in the United States? Is Duracade being sold or planted in Canada this year?*

Syngenta waited less than a year to commercialize Duracade 5307 in the United States after receiving U.S. regulatory approval for cultivation and planting. This occurred prior to obtaining many import market approvals. China's biotech regulatory-approval process starts after the commodity is deregulated or approved in the exporting country (in this case, the

United States), and as noted previously normally takes at least two years to complete. In some cases like China, commercializing this quickly does not provide even the minimum amount of time under its regulations to consider import approval.

The United States is the only corn exporting country in which Duracade 5307 is being launched in 2014. In contrast, in a March 10, 2014 NK update from Syngenta Canada Inc., it announced it would not proceed with commercial sale of Duracade hybrids for planting in 2014 in Canada. It instructed that any seed containing Duracade that had been shipped to Canada "cannot be sold," and that "arrangements for immediate returns will be made." The Syngenta Canada notice specifically referenced the lack of import approvals for Duracade in China and Europe, stating: "*Accordingly, we want to ensure the acceptance of any trait technology grown in Canada meets end market destination requirements.*" [Emphasis added.]

4. *Hasn't Syngenta entered into an agreement with Gavilon Grain LLC to assist in marketing Duracade 5307? Won't this prevent Duracade 5307 from getting into export markets where it's not approved?*

Syngenta has stated that Gavilon Grain LLC will accept grain containing Agrisure Duracade 5307 at "market price while providing stewardship and distribution services" for producers who are not able to find another market outlet for their harvested crops.

But given the zero-tolerance policy for unapproved biotech-enhanced traits enforced by China and other foreign countries, there are no guarantees – despite best efforts – that some level of Duracade 5307 will not become present in U.S. corn export shipments. The expansive geographic area in which Duracade 5307 seed is being marketed, the number of acres and producers believed to be involved in planting such seed, and the potential for pollen drift, cross-pollination and commingling make achieving a zero tolerance virtually impossible. In fact, private tests conducted when Viptera MIR 162 was commercialized showed a significant risk for low-level detections of that trait in corn harvested from fields where it was not planted.

Further, neither Syngenta nor Gavilon have said they will be financially responsible for economic losses if Duracade is detected in U.S. shipments to export markets for which it is not approved. [See question #5.] The combination of these factors adds a significant element of market risk that exporters evaluate when making individual company decisions on whether to market U.S. corn, co-products and other commodities to such foreign markets.

5. *What has Syngenta stated about the obligations and liabilities of growers if they choose to plant Agrisure Duracade corn in 2014?*

Syngenta says it will require growers to sign a Stewardship Agreement. One of the "grower responsibilities" contained in that agreement states that "the grower agrees to channel grain produced from seed products (whether corn or soybeans) to appropriate markets as necessary to prevent movement to markets where the grain has not yet received regulatory approval for import."

The grower agreement also contains a section entitled "General Provisions," which includes language under which the grower consents to understanding that "grain harvested from corn hybrids containing the Agrisure Technologies and DAS Technologies, or soybean varieties containing the Genuity RR2Y Technology or LibertyLink Technology, may not be fully approved for all grain exports markets."

Further, in a March 11, 2014 letter to member companies of the NGFA and North American Export Grain Association (NAEGA), Syngenta wrote that, "the grower remains responsible for planting, harvesting, and stewardship of seed and grain, just as members of the grain handling industry purchasing grain and reselling it remain solely liable for any risks or liabilities arising from their commercial activity." *[Emphasis added.]*

In several meetings with NGFA and NAEGA officials, Syngenta representatives have rejected direct requests to bear commercial responsibility (financial liability) if and when Duracade 5307 is detected in U.S. export shipments to countries where it is not approved for import.

6. *How much U.S. corn was disrupted by the detection of Agrisure Viptera MIR 162 in U.S. shipments?*

NGFA's analysis found that aggregated data supplied by U.S. exporters showed that between mid-November 2013 and March 2014, a total of 3.327 million metric tons (131 million bushels) of U.S. corn were subjected to either rejected or diverted shipments, or to canceled or deferred sales. In addition, trace levels of MIR 162 were detected in several U.S. soybean shipments to China, which caused those shipments to be detained.

7. *How big of an export market was China expected to be for U.S. corn before these trade disruptions occurred?*

The U.S. Department of Agriculture (USDA) forecasts that China will become the world's largest corn importer by 2020. China is projected to increase its corn imports to 22 million metric tons (866 million bushels) by 2023, up from 2.7 million metric tons (106 million bushels) in 2012. For 2013, USDA had projected that the United States would export 37 million metric tons (1.457 million bushels) of corn, and that China would import an estimated 7 million metric tons (276 million bushels) – virtually all of it from the United States. But U.S. corn shipments to China reported on an aggregated basis by U.S. exporters totaled only 1.23 million metric tons (48 million bushels) at the time the United States was effectively shut out of the Chinese market following the detections of MIR 162 in U.S. shipments.

Exports also are extremely important to U.S. soybean growers. USDA projects that 48 percent of the entire 2013 U.S. soybean crop will be exported, with nearly two-thirds of total U.S. soybean export sales for the 2013/14 marketing year destined for China.

8. *What kind of communications might be useful now between corn sellers and buyers?*

NGFA encourages corn buyers and sellers in the value chain to communicate concerning any limitations or restrictions buyers may have on accepting biotech-enhanced traits that do not have certain export market approvals. Each company will make its own independent business decisions in this regard based upon its market opportunities, market risks and other factors. For this reason, different companies or facilities may have different policies. For example, some companies or facilities may be unwilling to accept biotech-enhanced traits that are not approved in U.S. export markets because of the importance of international trade to their business or to U.S. facilities to which they sell. In other cases, facilities that may be willing to accept biotech-enhanced commodities that do not have export market approvals may want sellers to communicate in advance which loads have those traits so the facility can take steps to segregate and attempt to keep the product from entering export markets for which they are not approved. In still other cases, a company or facility may be located in an area dominated by domestic uses of corn (such as livestock feed markets) where traits unapproved for export markets can be utilized.

Farmers also are encouraged to read and fully understand Syngenta's grower agreement, and the legal obligations that apply to farmers planting and harvesting Duracade 5307.

-30-

About National Grain and Feed Association (NGFA): The NGFA consists of more than 1,000 grain, feed, grain processing and grain-related companies that operate approximately 7,000 facilities that handle about 70 percent of all U.S. grains and oilseeds. NGFA's membership includes grain elevators; feed and feed ingredient manufacturers; biofuels companies; grain and oilseed processors and millers; exporters; livestock and poultry integrators; and associated firms that provide goods and services to the industry. Also affiliated with the NGFA are 26 state and regional grain and feed associations.

The NGFA strongly supports agricultural biotechnology and other scientific and technological innovations that contribute to efficient production and availability of a safe, abundant, affordable, high-quality and sustainable food and feed supply for U.S. and world consumers. In this regard, the NGFA is working in tandem with the North American Export Grain Association, agricultural producer and commodity organizations, biotechnology providers and the seed industry in striving to improve the timeliness and synchronization of U.S. and foreign governmental approvals of biotech-enhanced traits.

EXHIBIT E

~~As filed with the Securities and Exchange Commission on February 13, 2014~~

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 20-F

☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE
SECURITIES EXCHANGE ACT OF 1934

OR

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2013

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

OR

☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Commission file number: 1-15152

SYNGENTA AG

(Exact name of Registrant as specified in its charter)

Switzerland

(Jurisdiction of incorporation or organization)

Schwarzwaldallee 215, 4058 Basel, Switzerland
(Address of principal executive offices)

James Halliwell
+41 61 323 7074

james.halliwell@syngenta.com
Syngenta International AG

P.O. Box
CH-4002 Basel, Switzerland

(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)

Securities registered or to be registered pursuant to Section 12(b) of the Act:

| Title of each class | Name of each exchange on which registered |
|--|---|
| American Depositary Shares, each representing one-fifth of a common share of Syngenta AG, nominal value CHF 0.10 | New York Stock Exchange |

Securities registered or to be registered pursuant to Section 12(g) of the Act: **None**

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: **None**

Indicate the number of outstanding shares of each of the Issuer's classes of capital or common stock as of the close of the period covered by the annual report.
93,126,149 Common shares, nominal value CHF 0.10 each

Table of Contents

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

☒ Yes ☐ No

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

☐ Yes ☒ No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

☐ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☒

Accelerated filer ☐

Non-accelerated filer ☐

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

U.S. GAAP ☐

International Financial Reporting Standards as issued by the
International Accounting Standards Board ☒

Other ☐

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

☐ Yes ☒ No

Table of Contents

Introduction

NATURE OF OPERATIONS

Syngenta AG ("Syngenta" or the "Company") is a world leading agribusiness operating in the Crop Protection and Seeds business, which is involved in the discovery, development, manufacture and marketing of a range of products designed to improve crop yields and food quality, and in the Lawn and Garden business, which provides professional growers and consumers with flowers, turf and landscape products.

Syngenta is headquartered in Basel, Switzerland and was formed by Novartis AG ("Novartis") and AstraZeneca PLC ("AstraZeneca") in November 2000 through an agreement to spin off and merge the Novartis crop protection and seeds businesses with the Zeneca agrochemicals business to create a dedicated agribusiness company whose shares were then the subject of a global offering (the "Transactions"). The Transactions were completed on November 13, 2000.

FORWARD-LOOKING STATEMENTS

The statements contained in this annual report that are not historical facts, including, without limitation, statements regarding management's expectations, targets or intentions, including for sales, earnings and earnings per share, constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and are based on the current expectations and estimates of Syngenta's management. Investors are cautioned that such forward-looking statements involve risks and uncertainties, and that actual results may differ materially.

Syngenta identifies the forward-looking statements in this annual report by using the words "expect", "would", "will", "potential", "plans", "prospects", "anticipates", "estimated", "believes", "intends", "aiming", "on track", or similar expressions, or the negative of these expressions. Syngenta cannot guarantee that any of the events or trends anticipated by the forward-looking statements will actually occur. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among other things:

- the risk that research and development will not yield new products that achieve commercial success;
- the risks associated with increasing competition in the industry;
- the risk that economic and/or financial market weakness may have a material adverse effect on Syngenta's results and financial position;
- the risk that customers will be unable to pay their debts to Syngenta due to economic conditions;
- the risk that Syngenta will not be able to obtain or maintain the necessary regulatory approvals for its business;
- the risks associated with potential changes in policies of governments and international organizations;
- the risks associated with exposure to liabilities resulting from environmental and health and safety laws;
- the risk that important patents and other intellectual property rights may be challenged or used by other parties;
- the risk that Syngenta may encounter problems when implementing significant organizational changes;
- the risk that the value of Syngenta's intangible assets may become impaired;
- the risk of substantial product liability or personal injury claims;
- the risk that consumer resistance to genetically modified crops and organisms may negatively impact sales;
- the risk that resistance to the use of products derived through biotechnology could decrease which could adversely affect sales of products used for crop protection;
- the risks associated with climatic variations;
- the risks associated with exposure to fluctuations in foreign currency exchange rates;

Table of Contents

- the risks associated with entering into single-source supply arrangements;
- the risks associated with conducting operations in certain territories that have been identified by the US government as state sponsors of terrorism;
- the risks associated with natural disasters;
- the risk that Syngenta's effective tax rate may increase;
- the risk of significant breaches of data security or disruptions of information technology systems;
- the risks that Syngenta now considers immaterial, but that in the future prove to become material; and
- other risks and uncertainties that are not known to Syngenta or are difficult to predict.

Some of these factors are discussed in more detail herein, including under Item 3 "Key Information", Item 4 "Information on the Company", and Item 5 "Operating and Financial Review and Prospects". Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Syngenta does not intend or assume any obligation to update these forward-looking statements.

Table of Contents

TABLE OF CONTENTS

| | |
|---|-----|
| <u>Introduction</u> | i |
| <u>NATURE OF OPERATIONS</u> | i |
| <u>FORWARD-LOOKING STATEMENTS</u> | i |
| <u>PART I</u> | 1 |
| <u>Item 1 — Identity of Directors, Senior Management and Advisers</u> | 1 |
| <u>Item 2 — Offer Statistics and Expected Timetable</u> | 1 |
| <u>Item 3 — Key Information</u> | 1 |
| <u>Item 4 — Information on the Company</u> | 11 |
| <u>Item 4A — Unresolved Staff Comments</u> | 38 |
| <u>Item 5 — Operating and Financial Review and Prospects</u> | 39 |
| <u>Item 6 — Directors, Senior Management and Employees</u> | 83 |
| <u>Item 7 — Major Shareholders and Related Party Transactions</u> | 119 |
| <u>Item 8 — Financial Information</u> | 121 |
| <u>Item 9 — The Offer and Listing</u> | 122 |
| <u>Item 10 — Additional Information</u> | 124 |
| <u>Item 11 — Quantitative and Qualitative Disclosures About Market Risk</u> | 136 |
| <u>Item 12 — Description of Securities Other Than Equity Securities</u> | 141 |
| <u>PART II</u> | 142 |
| <u>Item 13 — Defaults, Dividend Arrearages and Delinquencies</u> | 142 |
| <u>Item 14 — Material Modifications to the Rights of Security Holders and Use of Proceeds</u> | 142 |
| <u>Item 15 — Controls and Procedures</u> | 142 |
| <u>Item 16 — [Reserved]</u> | 142 |
| <u>Item 16A — Audit Committee Financial Expert</u> | 143 |
| <u>Item 16B — Code of Ethics</u> | 143 |
| <u>Item 16C — Principal Accountant Fees and Services</u> | 143 |
| <u>Item 16D — Exemptions from the Listing Standards for Audit Committees</u> | 144 |
| <u>Item 16E — Purchases of Equity Securities by the Issuer and Affiliated Purchasers</u> | 144 |
| <u>Item 16F — Change in Registrant's Certifying Accountant</u> | 145 |
| <u>Item 16G — Corporate Governance</u> | 145 |
| <u>Item 16H — Mine Safety Disclosure</u> | 145 |
| <u>PART III</u> | 146 |
| <u>Item 17 — Financial Statements</u> | 146 |
| <u>Item 18 — Financial Statements</u> | 146 |
| <u>Item 19 — Exhibits</u> | 147 |

Table of Contents

PART I

ITEM 1 — IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS

Not applicable.

ITEM 2 — OFFER STATISTICS AND EXPECTED TIMETABLE

Not applicable.

ITEM 3 — KEY INFORMATION

Financial Highlights

Syngenta has prepared the consolidated financial statements in US dollars (\$) and in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (IFRS). Financial figures are presented in millions of dollars (\$m) except where otherwise stated. The basis of preparation of the consolidated financial statements and the key accounting policies are discussed in Note 1 and in Notes 2 and 30, respectively, to the consolidated financial statements in Item 18.

The selected financial highlights information in accordance with IFRS presented below has been extracted from the consolidated financial statements of Syngenta. Investors should read the entire consolidated financial statements and not rely on the summarized information. The information includes the results of operations and the net assets of Circle One Global Inc. from May 15, 2009, Goldsmith Seeds Europe B.V. from September 23, 2009, Pybas Vegetable Seed Co., Inc. from December 16, 2009, Synergene Seed & Technology, Inc. from December 23, 2009, Maribo Seed International ApS from September 30, 2010, Greenleaf Genetics LLC from November 8, 2010, Agrosan S.A. from March 9, 2011, Pasteuria Bioscience Inc. from November 8, 2012, Sunfield Seeds Inc. from November 29, 2012, Dewgen N.V. from December 12, 2012 and MRI Seed Zambia Ltd and MRI Agro Zambia Ltd from October 31, 2013. For further information about these and other acquisitions, see Note 3 to the consolidated financial statements in Item 18.

Table of Contents

Financial highlights

| | Year ended December 31, | | | | |
|---|-------------------------|-------------------|-------------------|-------------------|-------------------|
| (\$m, except where otherwise stated) | 2013 | 2012 ¹ | 2011 ¹ | 2010 ¹ | 2009 ¹ |
| Amounts in accordance with IFRS | | | | | |
| Income statement data: | | | | | |
| Sales | 14,688 | 14,202 | 13,268 | 11,641 | 10,992 |
| Cost of goods sold | (7,986) | (7,223) | (6,790) | (5,904) | (5,573) |
| Gross profit | 6,702 | 6,979 | 6,478 | 5,737 | 5,419 |
| Operating expenses | (4,616) | (4,723) | (4,469) | (3,978) | (3,619) |
| Operating income | 2,086 | 2,256 | 2,009 | 1,759 | 1,800 |
| Income before taxes | 1,934 | 2,116 | 1,859 | 1,643 | 1,675 |
| Net income | 1,649 | 1,850 | 1,570 | 1,378 | 1,397 |
| Net income attributable to Syngenta AG shareholders | 1,644 | 1,847 | 1,569 | 1,373 | 1,394 |
| Number of shares – basic | 91,952,222 | 91,644,190 | 91,892,275 | 92,687,903 | 93,154,537 |
| Number of shares – diluted | 92,459,306 | 92,132,922 | 92,383,611 | 93,225,303 | 93,760,196 |
| Basic earnings per share (\$) | 17.88 | 20.16 | 17.07 | 14.81 | 14.96 |
| Diluted earnings per share (\$) | 17.78 | 20.05 | 16.98 | 14.73 | 14.86 |
| Cash dividends declared: | | | | | |
| Swiss franc ("CHF") per share | 9.50 | 8.00 | 7.00 | 6.00 | 6.00 |
| \$ per share equivalent | 10.01 | 8.82 | 7.64 | 5.61 | 5.27 |
| Cash flow data: | | | | | |
| Cash flow from operating activities | 1,214 | 1,359 | 1,871 | 1,707 | 1,419 |
| Cash flow used for investing activities | (772) | (1,218) | (472) | (450) | (880) |
| Cash flow from (used for) financing activities | (1,114) | (232) | (1,684) | (844) | 170 |
| Capital expenditure on tangible fixed assets | (625) | (508) | (479) | (396) | (652) |
| Balance sheet data: | | | | | |
| Current assets less current liabilities | 3,990 | 4,537 | 4,107 | 4,363 | 4,583 |
| Total assets | 20,216 | 19,438 | 17,241 | 17,285 | 16,162 |
| Total non-current liabilities | (3,356) | (4,226) | (4,063) | (4,483) | (5,339) |
| Total liabilities | (10,712) | (10,653) | (9,706) | (9,836) | (9,650) |
| Share capital | (6) | (6) | (6) | (6) | (6) |
| Total shareholders' equity | (9,491) | (8,774) | (7,526) | (7,439) | (6,498) |
| Other supplementary income data: | | | | | |
| Diluted earnings per share from continuing operations, excluding restructuring and impairment (\$) ² | 19.30 | 22.03 | 19.03 | 16.18 | 16.00 |

All activities were in respect of continuing operations.

Notes

- 1 In the consolidated financial statements in Item 18, Syngenta has adopted IAS 19 "Employee Benefits" (revised June 2011). Syngenta has also early adopted "Defined Benefit Plans: Employee Contributions", Amendments to IAS 19, issued in November 2013. Comparative amounts for the years 2009, 2010, 2011 and 2012 have been restated to reflect the revised IAS 19. The main changes that the revised IAS 19 introduces and the effect of the adoption on each financial statement line for the years ended 2012 and 2011 are detailed in Note 2 to the consolidated financial statements in Item 18. The effect of the adoption on the years ended 2010 and 2009 are as follows:

Table of Contents

| (\$m, except per share amounts) | 2010 | | | 2009 | | |
|---|-------------|--------------------|--------------------------|-------------|--------------------|--------------------------|
| | As reported | Adoption of IAS 19 | After adoption of IAS 19 | As reported | Adoption of IAS 19 | After adoption of IAS 19 |
| Cost of goods sold | (5,900) | (4) | (5,904) | (5,572) | (1) | (5,573) |
| Gross profit | 5,741 | (4) | (5,737) | 5,420 | (1) | 5,419 |
| Operating expenses | (3,948) | (30) | (3,978) | (3,601) | (18) | (3,619) |
| Operating income | 1,793 | (34) | 1,759 | 1,819 | (19) | 1,800 |
| Income before taxes | 1,677 | (34) | 1,643 | 1,694 | (19) | 1,675 |
| Net income | 1,402 | (24) | 1,378 | 1,411 | (14) | 1,397 |
| Net income attributable to Syngenta AG shareholders | 1,397 | (24) | 1,373 | 1,408 | (14) | 1,394 |
| Basic earnings per share (\$) | 15.07 | (0.26) | 14.81 | 15.11 | (0.15) | 14.96 |
| Diluted earnings per share (\$) | 14.99 | (0.26) | 14.73 | 15.01 | (0.15) | 14.86 |
| Current assets less current liabilities | 4,363 | - | 4,363 | 4,583 | - | 4,583 |
| Total assets | 17,285 | - | 17,285 | 16,129 | 33 | 16,162 |
| Total non-current liabilities | (4,483) | - | (4,483) | (5,331) | (8) | (5,339) |
| Total liabilities | (9,836) | - | (9,836) | (9,642) | (8) | (9,650) |
| Total shareholders' equity | (7,439) | - | (7,439) | (6,473) | (25) | (6,498) |
| Diluted earnings per share from continuing operations, excluding restructuring and impairment (\$) ² | 16.44 | (0.26) | 16.18 | 16.15 | (0.15) | 16.00 |

2 Diluted earnings per share from continuing operations, excluding restructuring and impairment is a non-GAAP measure.

A non-GAAP measure is a numerical measure of financial performance, financial position or cash flow that either:

- includes, or is subject to adjustments that have the effect of including, amounts that are excluded in the most directly comparable measure calculated and presented under IFRS as issued by the IASB, or
- excludes, or is subject to adjustments that have the effect of excluding, amounts that are included in the most directly comparable measure calculated and presented under IFRS as issued by the IASB.

Table of Contents

Restructuring represents the effect on reported performance of initiating and enabling business changes that are considered major and that, in the opinion of management, will have a material effect on the nature and focus of Syngenta's operations, and therefore require separate disclosure to provide a more thorough understanding of business performance. Restructuring includes the incremental costs of closing, restructuring or relocating existing operations, and gains or losses from related asset disposals. Restructuring also includes the effects of completing and integrating significant business combinations and divestments, including related transaction costs, gains and losses. Recurring costs of normal business operations and routine asset disposal gains and losses are excluded. Impairment includes impairment losses associated with major restructuring as well as impairment losses and reversals of impairment losses resulting from major changes in the markets in which a reported segment operates.

Further discussion on the reason for including disclosure of this and other non-GAAP measures is included in Appendix A at the end of the Operating and Financial Review and Prospects in Item 5.

Restructuring and impairment charges for 2013, 2012 and 2011 are analyzed in Note 6 to the consolidated financial statements in Item 18. Restructuring for 2010 and 2009 mainly related to the Operational Efficiency program announced in 2004 representing the costs of closure of certain manufacturing and research and development sites and refocusing of other continuing sites and also to the further phase of the Operational Efficiency program announced in 2007 to drive cost savings to offset increased expenditure in research and technology, marketing and product development in the growth areas of Seeds, professional products and emerging country markets.

A detailed reconciliation of net income and earnings per share before restructuring and impairment to net income and earnings per share according to IFRS is presented in Appendix A at the end of the Operating and Financial Review and Prospects in Item 5.

Risk Factors

Syngenta's business, financial condition, results of operations or cash flows could suffer material adverse effects due to any of the following risks. Risks that are considered to be material are described below.

The resources Syngenta devotes to research and development may not result in commercially viable products

Syngenta's success depends in part on its ability to develop new products. Research and development in the agribusiness industry is expensive and prolonged, and entails considerable uncertainty. The process of developing a novel crop protection product, plant variety or trait typically takes about six to ten years from discovery through testing and registration to initial product launch, but this period varies considerably from product to product and country to country. Because of the complexities and uncertainties associated with chemical and biotechnological research, compounds or biotechnological products currently under development may neither survive the development process nor ultimately receive the requisite regulatory approvals needed to market such products. Even when such approvals are obtained, there can be no assurance that a new product will be commercially successful. In addition, research undertaken by competitors may lead to the launch of competing or improved products which may affect sales of Syngenta's new products.

Syngenta faces increasing competition in its industry

Syngenta currently faces significant competition in the markets in which it operates. In most segments of the market, the number of products available to the grower is steadily increasing as new products are introduced, although this trend can be partly offset by the withdrawal of some products because they are not re-registered or are subject to voluntary range reduction programs to reduce the range of products offered. At the same time, an increasing number of products are coming off patent and are thus available to generic manufacturers for production. As a result, Syngenta anticipates that it will continue to face significant competitive challenges.

Table of Contents

Economic and/or financial market weakness may have a material adverse effect on Syngenta's results and financial position

Commodity crop prices have historically been volatile and downturns in prices can indirectly affect Syngenta's results by adversely affecting the income and financial position of Syngenta's customers and of the users of Syngenta's products. This may result in reduced sales, competitive price pressure in Syngenta's markets and in slower collection of accounts receivable. A low availability of credit may also limit the amount of business Syngenta's customers and suppliers can transact with Syngenta, including customers and suppliers in parts of the Eurozone, which continue to experience economic problems. These occurrences may negatively impact Syngenta's business, results of operations or cash flows. Because of the high proportion of costs which are fixed in nature, Syngenta may not be able to compensate fully for these effects in the short term through measures such as reducing expenses.

While Syngenta views its current credit facilities and ability to access capital markets as adequate for its needs, difficulties in the banking sector in the future or illiquidity in the credit or capital markets may restrict Syngenta's ability to raise additional funds or increase the cost of such funding.

Significant declines in asset prices or changes to long-term assumptions may cause funding levels in Syngenta's externally funded defined benefit pension plans to fall below stipulated regulatory levels. This may require Syngenta to pay additional contributions to restore funding to required levels. Please see Notes 2 and 22 to the consolidated financial statements in Item 18 for further information about Syngenta's defined benefit pension plans and the assumptions used to measure the related pension liabilities.

Syngenta's customers may be unable to pay their debts to Syngenta due to economic conditions

Normally Syngenta delivers its products against future payment. Syngenta's credit terms vary according to local market practice, with credit terms for customers typically ranging from 30 to 180 days, except for customers in some emerging markets, where credit terms may range from cash on delivery to, in certain cases, 360 days. Syngenta's customers, particularly in developing economies and in economies experiencing an economic downturn, such as parts of the Eurozone, may be exposed to business, political or financial conditions impacting their ability to pay their debts, which could adversely affect Syngenta's results. See Item 5 for information regarding the amount of receivables Syngenta has with customers in the five main distressed Eurozone countries (Greece, Italy, Ireland, Spain and Portugal) and in Argentina. While Syngenta uses barter and other security arrangements to reduce customer credit exposure in some emerging markets, it may still be exposed to risk of material losses from its credit exposure in these markets.

Syngenta may not be able to obtain or maintain the necessary regulatory approvals for some of its products, which could restrict its ability to sell those products in some markets

Syngenta's products must receive regulatory approval before they can be marketed, but Syngenta may not be able to obtain such approvals. In most markets, including the United States and the European Union, crop protection products must be registered after being tested for safety, efficacy and environmental impact. In most of Syngenta's principal markets, after a period of time, Syngenta must also re-register its crop protection products and show that they meet all current standards, which may have become more stringent since the prior registration. For seeds products, in the European Union, a new plant variety will be registered only after it has been shown that it is distinct, uniform, stable, and better than existing varieties. Delays in obtaining regulatory approvals to import crops grown from seed containing certain traits may influence the rate of adoption of new genetically modified products in globally traded crops.

Regulatory standards and trial procedures are continuously changing. Responding to these changes and meeting existing and new requirements may be costly and burdensome. In addition, changing regulatory standards may affect Syngenta's ability to maintain its products on the market. A current example is the European Commission's two year restriction on the use of neonicotinoid insecticides on certain crops due to the alleged impact of these products on bee populations. For further information regarding this restriction, see Item 4 – Business Overview – Key Marketed Products – Crop Protection.

Table of Contents

Changes in the agricultural and certain other policies of governments and international organizations may prove unfavorable

In subsidized markets such as the United States, the European Union and certain markets in Asia including Japan, reduction of subsidies to growers may inhibit the growth of markets for products used in agriculture. In each of these areas there are various pressures to reduce subsidies. In addition, changes in governmental policies that impact agriculture, for example the US government policy on renewable fuels, may similarly inhibit the growth of markets for products used in agriculture. However, it is difficult to predict accurately whether, and if so when, such changes will occur. Syngenta expects that the policies of governments and international organizations will continue to affect the income available to growers to purchase products used in agriculture and, accordingly, the operating results of the agribusiness industry.

Syngenta is subject to stringent environmental, health and safety laws, regulations and standards, which can result in compliance costs and remediation efforts that may adversely affect its operational and financial position

Syngenta is subject to a broad range of increasingly stringent laws, regulations and standards in all of its operational jurisdictions. This results in significant compliance costs and can expose Syngenta to legal liability. These requirements are comprehensive and cover many activities including: air emissions, waste water discharges, the use and handling of hazardous materials, waste disposal practices, the clean-up of existing environmental contamination and the use of chemicals and genetically modified seeds by growers.

Environmental and health and safety laws, regulations and standards expose Syngenta to the risk of substantial costs and liabilities, including liabilities associated with assets that have been sold and activities that have been discontinued. In addition, many of Syngenta's manufacturing sites have a long history of industrial use. As is typical for businesses like Syngenta's, soil and groundwater contamination has occurred in the past at some sites, and may be identified at other sites in the future. Disposal of waste from its business at off-site locations also exposes Syngenta to potential remediation costs. Consistent with past practice, Syngenta is continuing to investigate and remediate, or monitor soil and groundwater contamination at a number of these sites. Despite its efforts to comply with environmental laws, Syngenta may face remediation liabilities and legal proceedings concerning environmental matters.

Based on information presently available, Syngenta has budgeted expenditures for environmental improvement projects and has established provisions for known environmental remediation liabilities that are probable and capable of estimation. However, it cannot predict environmental matters with certainty, and the budgeted amounts and established provisions may not be adequate for all purposes. In addition, the development or discovery of new facts, events, circumstances, changes in law or conditions, including future decisions to close plants which may trigger remediation liabilities, could result in increased costs and liabilities or prevent or restrict some of Syngenta's operations.

Efforts by Syngenta to protect its intellectual property rights or defend against claims asserting that Syngenta has infringed the intellectual property rights of others may be unsuccessful

Scientific and technological innovation is critical to the long-term success of Syngenta's businesses. However, third parties may challenge the measures that Syngenta takes to protect processes, compounds, organisms and methods of use through patents and other intellectual property rights and, as a result, Syngenta's products may not always have the full benefit of intellectual property rights. In addition, while Syngenta takes steps to prevent unauthorized access to and distribution of its intellectual property, it cannot assure that unauthorized parties do not obtain access to and use such property.

Table of Contents

Third parties may also claim that Syngenta's products violate their intellectual property rights. Defending such claims, even those without merit, could be time-consuming and expensive. In addition, any such claim could also result in Syngenta having to enter into license arrangements, develop non-infringing products or engage in litigation that could be costly.

Legislation and jurisprudence on patent protection in major markets such as the United States and the European Union is evolving and changes in laws could affect Syngenta's ability to obtain or maintain patent protection for its products.

Problems encountered by Syngenta when implementing significant organizational changes could adversely affect the future performance of the Company

Syngenta expects to continue to engage in restructuring activities to reduce operating costs, increase sales, or both. In addition, Syngenta may acquire or dispose of significant businesses, which would necessitate restructuring its operations. Syngenta may fail to adequately implement such restructuring activities in the manner contemplated, which could cause the restructuring activities to fail to achieve the desired results. Even if Syngenta does implement the restructuring activities in the manner contemplated, they may not produce the desired results. Accordingly, such restructuring activities may not reduce operating costs or increase sales. Failure to adequately implement significant restructuring activities could have a material adverse effect on Syngenta's business and consequently impact its financial position, results of operations and cash flows.

The value of Syngenta's intangible assets, including goodwill arising from acquisitions, may become impaired

Syngenta has a significant amount of intangible assets, including goodwill, on its consolidated balance sheet and, if it continues to acquire businesses in the future, may record significant additional intangible assets and goodwill. As described in Note 2 and 30 to the consolidated financial statements in Item 18, Syngenta regularly tests its intangible assets for impairment. Upon completing its testing for 2013, which included subjecting the assumptions used in the testing to a sensitivity analysis, Syngenta recorded impairments of intangible assets totaling \$23 million. Otherwise, Syngenta has concluded that no material intangible assets are impaired at December 31, 2013. However, unforeseen events that occur in the future may result in actual future cash flows for Syngenta's businesses being different from those forecasted. As a consequence, Syngenta's intangible assets could become impaired and the resulting impairment losses could have a material adverse impact on Syngenta's financial position and results of operations.

Syngenta may be required to pay substantial damages as a result of product liability or personal injury claims for which insurance coverage is not available

Product liability and personal injury claims are a commercial risk for Syngenta, particularly as it is involved in the supply of chemical products which can be harmful to humans and the environment. Courts have levied substantial damages in the United States and elsewhere against a number of companies in the agribusiness industry in past years based upon claims for injuries allegedly caused by the use of their products. While a global insurance program is in place, a substantial product liability or personal injury claim that is not covered fully or at all by insurance could have a material adverse effect on Syngenta's operating results or financial condition.

Consumer and government resistance to genetically modified organisms may negatively affect Syngenta's public image and reduce sales

Syngenta is active in the field of genetically modified organisms in the seeds area and in biotechnology research and development in seeds and crop protection. However, the high public profile of biotechnology and lack of consumer acceptance of products to which Syngenta has devoted substantial resources could negatively affect its public image and results. The current resistance from consumer groups, particularly in Europe, to products based on genetically modified organisms, because of concerns over their effects on food safety and the environment, may spread to and influence the acceptance of products developed through biotechnology in other regions of the world, which could limit the commercial opportunities to exploit biotechnology. Actions by these groups may also disrupt research and development or production of genetically modified seeds. In addition, some government authorities have enacted, and others in the future might enact, regulations regarding genetically modified organisms which may delay and limit or even prohibit the development and sale of such products.

Table of Contents

Resistance to the use of products derived through biotechnology could decrease which could adversely affect sales of products used for crop protection

Resistance to allowing the use of genetically modified seeds in certain parts of the world, including the European Union, could decrease resulting in growers there replacing crop protection technology with biotechnology, which would adversely impact Syngenta's sales of products used for crop protection. This impact may not be offset, in whole or in part, by the opportunity for Syngenta to increase its sales of seeds having traits developed through biotechnology. Sales of products used for crop protection accounted for approximately 77 percent of Syngenta's total sales in 2013, whereas seeds accounted for approximately 23 percent of such sales.

Syngenta's results may be affected by climatic variations

The agribusiness industry is subject to seasonal and weather factors, which make its operations relatively unpredictable from period to period. The weather can affect the presence of disease and pests in the short term on a regional basis and, accordingly, can affect the demand for crop protection products and the mix of products used (positively or negatively). The weather also can affect the quality, volume and costs of seeds produced for sale. Seed yields can be higher or lower than planned and significantly higher yields could lead to Syngenta purchasing more seeds from contract growers than can be sold during the limited product life of the seeds, which could lead to inventory provisions and write-offs.

Currency fluctuations may have a harmful impact on Syngenta's financial results or may increase its liabilities

Syngenta reports its results in US dollars; however a substantial portion of sales and costs are denominated in currencies other than the US dollar. Fluctuations in the values of these currencies, especially in the US dollar against the Swiss franc, British pound, Euro and Brazilian real, can have a material impact on Syngenta's financial results. Also, an increasing amount of Syngenta's sales are in emerging markets, where currency exchange rates can be volatile and where hedging products are expensive or of limited availability. Fluctuations in these emerging market countries' exchange rates against the US dollar may adversely impact Syngenta's results through recognition of currency losses. In addition, several countries in the Eurozone have been experiencing financial difficulties. If a member state of the Eurozone were to decide to abandon the Euro as its lawful currency and introduce a new national currency, Syngenta could incur losses upon the lawful conversion to the new national currency of amounts receivable from customers in the member state that were originally denominated in Euros.

Syngenta maintains a single supplier for some raw materials, which may affect its ability to obtain sufficient amounts of those materials

While Syngenta generally maintains multiple sources of supply and obtains supplies of raw materials from a number of countries, there are a limited number of instances where Syngenta has entered into single-source supply contracts or where Syngenta routinely makes spot purchases from a single supplier in respect of active ingredients, intermediates or raw materials for certain important products. These instances occur where there is sufficient commercial benefit and security of supply can be assured, or where there is no viable alternative source of supply. Such single supplier arrangements accounted for approximately 16 percent of Syngenta's purchases in 2013 of active ingredients, intermediates and raw materials used in Crop Protection products, as determined by cost. Syngenta's ability to obtain sufficient amounts of those materials may be adversely affected by the unforeseen loss of a supplier or from a supplier's inability to meet its supply obligations. The percentage of single supplier arrangements could increase in the future if consolidation were to occur among multiple supply sources.

Table of Contents

Syngenta also has contracts with a number of suppliers for services, including information technology, telecommunications and finance transaction processing. The sudden failure by one of these service providers to meet its obligations could prove disruptive to normal operations for a protracted period and adversely impact Syngenta's financial results. To mitigate this risk, Syngenta limits major contracts only to large global suppliers providing such services as part of their core business and having a significant portfolio of clients receiving similar services. Syngenta continuously monitors these companies both on their performance with Syngenta and their overall health and market performance.

Syngenta conducts business in most countries of the world, including in certain high-risk countries, some of which have been identified by the US government as state sponsors of terrorism

Syngenta conducts business in most countries of the world, some of which are subject to a high level of political or economic instability that could impact Syngenta's ability to continue to operate there. Acts of terror or war may impede Syngenta's ability to operate in particular countries or regions, and may impede the flow of goods and services between countries. In addition, Syngenta has minor operations in Cuba, Iran and the Sudan, which have been identified by the US government as state sponsors of terrorism. Syngenta's operations in these countries are quantitatively immaterial, and it is Syngenta's belief that supporting agriculture in these countries is beneficial to their wider population, for whom food is often in short supply. However, certain investors may choose not to hold investments in companies that have operations of any size in these countries and several US states have enacted, and others may in the future enact, legislation requiring public entities with investments in companies with operations in these countries to disclose this fact or in some cases to divest these investments. Any such divestment is not currently expected to have a material impact on the value of Syngenta shares.

Natural disasters could adversely affect Syngenta's business

Natural disasters could affect Syngenta's or its suppliers' manufacturing and production facilities, which could affect Syngenta's costs or ability to meet supply requirements. Natural disasters could also affect Syngenta's customers, which could affect Syngenta's sales or its ability to collect receivables due from customers. Syngenta's corporate headquarters and other facilities are located near an earthquake fault line in Basel, Switzerland. Additionally, some of Syngenta's other significant facilities are located in areas where earthquakes, hurricanes or flooding are possible. The occurrence of a major earthquake, hurricane or flood at a Syngenta facility could result in loss of life, destruction of facilities and/or business interruption, which could have a material adverse effect on Syngenta's business.

An increase in Syngenta's group tax rate could occur, which would adversely affect its financial results

The effective tax rate on Syngenta's earnings depends largely on the mix of business activities and consequent taxable profit in countries in which Syngenta operates. Syngenta benefits from the fact that a portion of its earnings is taxed at more favorable rates in some jurisdictions outside Switzerland. Future changes in the mix of business activities, or in tax laws or their application with respect to matters such as transfer pricing, intra-group dividends, controlled companies or a restriction in tax relief allowed on the interest on intra-group debt, could increase Syngenta's effective tax rate and adversely affect its financial results. Syngenta has several open tax years in many jurisdictions, where tax calculations may be subject to adjustment. These matters are discussed in Notes 2 and 25 to the consolidated financial statements in Item 18.

Significant breaches of data security or disruptions of information technology systems could adversely affect Syngenta's business

Syngenta's business is increasingly dependent on critical, complex and interdependent information technology systems, including Internet-based systems, to support business processes as well as internal and external communications. The size and complexity of Syngenta's computer systems make them potentially vulnerable to data security breaches, whether by employees or others, which may result in unauthorized persons getting access to sensitive data. Such data security breaches could lead to the loss of trade secrets or other intellectual property. In addition, Syngenta's systems are potentially vulnerable to breakdown, malicious intrusion and computer viruses, which could disrupt production, order processing and shipping, cash receipts and disbursement processes, accounting and reporting processes, or other key business processes. A loss of trade secrets or other intellectual property, or systems-related disruption could have a material adverse effect on Syngenta's business, financial position, results of operations or cash flows.

Table of Contents

Syngenta's share price may be volatile and subject to sudden and significant drops

The trading price of Syngenta shares and ADSs has been, and could in the future continue to be, subject to significant fluctuations in response to variations in Syngenta's financial performance, regulatory and business conditions in its industry, general economic trends and other factors, some of which are unrelated to the operating performance of Syngenta.

If you hold Syngenta ADSs it may be more difficult for you to exercise your rights

The rights of holders of Syngenta ADSs are governed by the deposit agreement between Syngenta and The Bank of New York Mellon. These rights are different from those of holders of Syngenta shares in several respects, including the receipt of information, the receipt of dividends or other distributions, the exercise of voting rights and attendance at shareholders' meetings. As a result, it may be more difficult for a holder of Syngenta ADSs to exercise those rights.

Table of Contents

ITEM 4 — INFORMATION ON THE COMPANY

History and Development of the Company

The Company

Syngenta AG, a Swiss "Aktiengesellschaft", was formed on November 12, 1999 under the laws of Switzerland. Syngenta's business operations were created in 2000 by Novartis and AstraZeneca through an agreement to spin off and merge the Novartis agribusiness and the Zeneca agrochemicals business to create a dedicated agribusiness company whose shares were then the subject of a global offering. Both the Novartis and AstraZeneca agribusinesses had existed since the 1930's through a variety of legacy companies.

Syngenta is domiciled in and governed by the laws of Switzerland. It has its registered office and principal business office at Schwarzwaldallee 215, 4058 Basel, Switzerland. The telephone number of Syngenta is +41-61-323-1111.

Syngenta became a publicly listed company in 2000. At December 31, 2013, the company was listed on the SIX Swiss Exchange under the symbol SYNN and the New York Stock Exchange under the symbol SYT.

Investments and Divestments

Information on acquisitions, divestments and other significant transactions completed by Syngenta during each of the years ended December 31, 2013, 2012 and 2011 is included in Item 5 and in Note 3 to the consolidated financial statements in Item 18.

Table of Contents

Business Overview

Industry Overview

Syngenta is a world leading agribusiness operating in the crop protection, seeds and lawn and garden markets. Crop protection chemicals include herbicides, insecticides, fungicides and seed treatments to control weeds, insects and diseases in crops, and are essential inputs enabling growers around the world to improve agricultural productivity and food quality. In seeds, Syngenta operates in the high value commercial sectors of field crops (including corn, oilseeds, cereals and sugar beet) and vegetables. The lawn and garden business provides professional growers and consumers with flowers, turf and landscape products.

Syngenta's Business

Syngenta's business is divided into five reporting segments: the four geographic regions, Europe, Africa and Middle East, North America, Latin America and Asia Pacific, comprising the integrated Crop Protection and Seeds business; and the global Lawn and Garden business. These segments reflect the organizational and management structure that was implemented in connection with Syngenta's strategy, announced in 2011, to integrate its commercial operations across Crop Protection and Seeds using a new business model with a strategic crop focus. The commercial integration was completed in 2012 and Syngenta adopted in 2012 the new segment reporting of sales and profitability. These segments are described in greater detail below.

The following information, which appears in other parts of this Form 20-F, is incorporated herein by reference:

- Item 5 – Operating and Financial Review and Prospects – Results of Operations, the tabular information regarding:
 - o sales and operating income for the integrated Crop Protection and Seeds business and for each of the four geographic segments therein;
 - o sales by product line for the integrated Crop Protection and Seeds business; and
 - o sales and operating income for the global Lawn and Garden business.

Sales and operating income for the segments, as presented in Item 5 of this report, are seasonal. Results for the Europe, Africa and Middle East, North America and global Lawn and Garden segments are weighted towards the first half of the calendar year, which largely reflects the northern hemisphere planting and growing cycle. Results for the Latin America segment are weighted towards the second half of the calendar year, which largely reflects the southern hemisphere planting and growing cycle. Results for the Asia Pacific segment are weighted slightly towards the first half of the calendar year.

References in this document to Syngenta's competitive position, identified by terms such as "world-leading", "leader", "leading", "largest", "broadest", or similar expressions are based where possible on global agrochemical and biotechnology industry information provided by a third party or on information published by major competitors and are supplemented by Syngenta internal estimates.

Table of Contents

Integrated Business

Based on the combined strength of its Crop Protection and Seeds businesses, Syngenta regards itself as uniquely positioned to address the increasingly complex challenges facing farmers, through the development of fully integrated offers on a crop basis. The integrated business is structured into 19 territories grouped under the four geographic regions (Europe, Africa and Middle East, North America, Latin America and Asia Pacific). Under this integrated business, Syngenta is developing an expanded crop-based product pipeline and increasing its reach into new markets with new products, solutions and local go-to-market strategies.

Crop teams for each of eight strategic global crops work alongside territory and regional management to develop and maximize integrated product and service offers. The eight global crops comprise cereals (wheat, barley), corn, field crops (sunflower, oilseed rape, sugar beet), rice, soybean, specialty crops (e.g. fruits, trees, nuts, vines, potatoes, cotton, plantations), sugar cane and vegetables.

Estimated sales by crop for the years ended December 31, 2013 and 2012 are as follows:

| Estimated sales (\$m) | 2013 | 2012 | Change | |
|-----------------------|--------|--------|----------|--------|
| | | | Actual % | CER %* |
| Cereals | 1,772 | 1,599 | 11 | 12 |
| Corn | 3,560 | 3,612 | -1 | - |
| Field crops | 1,428 | 1,299 | 10 | 11 |
| Rice | 653 | 590 | 11 | 16 |
| Soybean | 2,577 | 2,341 | 10 | 11 |
| Specialty crops | 2,004 | 2,051 | -2 | -1 |
| Sugar cane | 290 | 259 | 12 | 15 |
| Vegetables | 1,701 | 1,670 | 2 | 4 |
| Other** | 12 | 24 | n/a | n/a |
| Total | 13,997 | 13,445 | 4 | 6 |

Precise sales by crop cannot be determined because many of Syngenta's Crop Protection products can be used on multiple crops. Estimated sales by crop for the year ended December 31, 2011 are not presented because reliable estimates were not available prior to the implementation in 2012 of the integrated business strategy.

* Change percentage at constant exchange rates ("CER"). For the definition of constant exchange rates, see Appendix A in Item 5.

** Sales of Materials Protection products.

Description of Products

Integrated Business

The development of integrated offers involves combining Syngenta's Crop Protection and Seeds products, and in some instances combining Syngenta's products with third party products and services, to provide growers with innovative ways to improve crop yields and quality. These offers include integrated crop management programs using existing and newly developed crop protection solutions, genetics, innovative genetically modified and native trait packages, and growing protocols.

Crop Protection

Syngenta is active in herbicides, especially for corn, cereals, soybean and rice; fungicides mainly for corn, cereals, fruits, grapes, rice, soybean and vegetables; insecticides for fruits, vegetables and field crops; and seed care, primarily in corn, soybean, cereals and cotton. Herbicides are products that prevent or reduce weeds that

Table of Contents

compete with the crop for nutrients, light and water. Herbicides can be subdivided into (i) selective herbicides, which are crop-specific and control weeds without harming the crop and (ii) non-selective herbicides, which reduce or halt the growth of all vegetation with which they come in contact. Fungicides are products that prevent and cure fungal plant diseases that affect crop yield and quality. Insecticides are products that control chewing pests such as caterpillars and sucking pests such as aphids, which reduce crop yields and quality. Seed care products are insecticides and fungicides used to protect growth during the early stages. Syngenta is also investing in bio pesticide solutions, which complement traditional Crop Protection chemistry.

Syngenta has a broad range of Crop Protection products, making it number one or two in all of its target sectors, underpinned by strong worldwide market coverage. Approximately 95 percent of Syngenta's annual sales of Crop Protection products come from products marketed in all four region segments.

Seeds

Syngenta produces and markets seeds and plants that have been developed using advanced genetics and related technologies. Syngenta sells seed products in all geographic territories.

Syngenta's seed portfolio is one of the broadest in the industry, offering over 200 product lines and over 6,800 varieties of Syngenta's own proprietary genetics. Syngenta divides its seeds products into field crops, such as corn, soybean, rice, cereals, oilseeds and sugar beet, and vegetables. Syngenta has a significant market share in vegetables, corn, soybean, cereals, sugar beet and sunflower. Seed products are derived from a germplasm pool and trait portfolio and developed further utilizing sophisticated plant-breeding methods. In addition to income from development and commercialization of transgenic products, income is generated from licensing arrangements.

Key Marketed Products and Services

Integrated Business

- **NUCOFFEE®** is Syngenta's innovative business model operating in Brazil that brings together growers, cooperatives and roasters. Built around Syngenta's crop protection, quality and barter programs, the NUCOFFEE® platform helps Brazilian coffee farmers increase their profitability, with higher yields and higher prices for their coffee crop.
- **PLENUS®** is a ready-to-plant soybean seed in Latin America combining high quality germplasm and novel professional seed treatment containing a long life inoculant, offering simplicity and crop safety to the grower.

Crop Protection

Selective herbicides

Syngenta has a broad range of Selective herbicides that control grasses and broad-leaved weeds and are applicable to most crops, with a special emphasis on corn and cereals.

- **Atrazine** (AATREX®/GESAPRIM®) acts mainly against broad-leaved weeds. Although Atrazine was introduced in 1957 and has been off patent for a number of years, it remains an important product for broad-leaved weed control in corn. Atrazine is marketed in North America, Latin America, Asia Pacific and in Africa and the Middle East.
- **Clodinafop** (TOPIK®/HORIZON®/ CELIO®/ DISCOVER®) is a grass herbicide which provides a broad spectrum of annual grass control in wheat. To further increase crop safety in cereals the active substance Clodinafop is mixed with the safener Cloquintocet, which selectively enhances the degradation of Clodinafop in wheat but not in the grass weeds. Clodinafop is marketed in all regions.

UNITED STATES DISTRICT COURT

for the

Eastern District of North Carolina

Richard Fredrick Lanier, et al.

Plaintiff(s)

V.

Syngenta AG, et al.

Defendant(s)

Civil Action No.

SUMMONS IN A CIVIL ACTION

To: *(Defendant's name and address)* Syngenta AG
Schwarzwaldallee 215
Basel-Stadt, Switzerland

A lawsuit has been filed against you.

Within 21 days after service of this summons on you (not counting the day you received it) — or 60 days if you are the United States or a United States agency, or an officer or employee of the United States described in Fed. R. Civ. P. 12 (a)(2) or (3) — you must serve on the plaintiff an answer to the attached complaint or a motion under Rule 12 of the Federal Rules of Civil Procedure. The answer or motion must be served on the plaintiff or plaintiff's attorney, whose name and address are: **Brian L. Kinsley**

Brian L. Kinsley
Crumley Roberts
2400 Freeman Mill Road
Greensboro, NC 27406

If you fail to respond, judgment by default will be entered against you for the relief demanded in the complaint. You also must file your answer or motion with the court.

CLERK OF COURT

Date: _____

Signature of Clerk or Deputy Clerk

Civil Action No. _____

PROOF OF SERVICE

(This section should not be filed with the court unless required by Fed. R. Civ. P. 4 (l))

This summons for *(name of individual and title, if any)* _____
was received by me on *(date)* _____.

☐ I personally served the summons on the individual at *(place)* _____
on *(date)* _____; or

☐ I left the summons at the individual's residence or usual place of abode with *(name)* _____
_____, a person of suitable age and discretion who resides there,
on *(date)* _____, and mailed a copy to the individual's last known address; or

☐ I served the summons on *(name of individual)* _____, who is
designated by law to accept service of process on behalf of *(name of organization)* _____
on *(date)* _____; or

☐ I returned the summons unexecuted because _____; or

☐ Other *(specify)*: _____

My fees are \$ _____ for travel and \$ _____ for services, for a total of \$ 0.00.

I declare under penalty of perjury that this information is true.

Date: _____

Server's signature

Printed name and title

Server's address

Additional information regarding attempted service, etc:

UNITED STATES DISTRICT COURT

for the

Eastern District of North Carolina

Richard Fredrick Lanier, et al,

Plaintiff(s)

v.

Syngenta AG, et al.

Defendant(s)

Civil Action No.

SUMMONS IN A CIVIL ACTION

To: *(Defendant's name and address)* Syngenta Crop Protection AG
Schwarzwaldallee 215
4058 Basel-Stadt
Switzerland

A lawsuit has been filed against you.

Within 21 days after service of this summons on you (not counting the day you received it) — or 60 days if you are the United States or a United States agency, or an officer or employee of the United States described in Fed. R. Civ. P. 12 (a)(2) or (3) — you must serve on the plaintiff an answer to the attached complaint or a motion under Rule 12 of the Federal Rules of Civil Procedure. The answer or motion must be served on the plaintiff or plaintiff's attorney, whose name and address are: Brian L. Kinsley
Crumley Roberts
2400 Freeman Mill Road
Greensboro, NC 27406

If you fail to respond, judgment by default will be entered against you for the relief demanded in the complaint. You also must file your answer or motion with the court.

CLERK OF COURT

Date: _____

Signature of Clerk or Deputy Clerk

Civil Action No. _____

PROOF OF SERVICE

(This section should not be filed with the court unless required by Fed. R. Civ. P. 4 (l))

This summons for *(name of individual and title, if any)* _____
was received by me on *(date)* _____.

☐ I personally served the summons on the individual at *(place)* _____
_____ on *(date)* _____; or

☐ I left the summons at the individual's residence or usual place of abode with *(name)* _____
_____, a person of suitable age and discretion who resides there,
on *(date)* _____, and mailed a copy to the individual's last known address; or

☐ I served the summons on *(name of individual)* _____, who is
designated by law to accept service of process on behalf of *(name of organization)* _____
_____ on *(date)* _____; or

☐ I returned the summons unexecuted because _____; or

☐ Other *(specify)*: _____

My fees are \$ _____ for travel and \$ _____ for services, for a total of \$ 0.00.

I declare under penalty of perjury that this information is true.

Date: _____

Server's signature

Printed name and title

Server's address

Additional information regarding attempted service, etc:

UNITED STATES DISTRICT COURT

for the

Eastern District of North Carolina

Richard Fredrick Lanier, et al.

Plaintiff(s)

v.

Syngenta AG, et al.

Defendant(s)

Civil Action No.

SUMMONS IN A CIVIL ACTION

To: *(Defendant's name and address)* Syngenta Corporation
3411 Silverside Road #100
Wilmington, DE 19810-4812

A lawsuit has been filed against you.

Within 21 days after service of this summons on you (not counting the day you received it) — or 60 days if you are the United States or a United States agency, or an officer or employee of the United States described in Fed. R. Civ. P. 12 (a)(2) or (3) — you must serve on the plaintiff an answer to the attached complaint or a motion under Rule 12 of the Federal Rules of Civil Procedure. The answer or motion must be served on the plaintiff or plaintiff's attorney, whose name and address are:

Brian L. Kinsley
Crumley Roberts
2400 Freeman Mill Road
Greensboro, NC 27406

If you fail to respond, judgment by default will be entered against you for the relief demanded in the complaint. You also must file your answer or motion with the court.

CLERK OF COURT

Date: _____

Signature of Clerk or Deputy Clerk

Civil Action No. _____

PROOF OF SERVICE

(This section should not be filed with the court unless required by Fed. R. Civ. P. 4 (l))

This summons for *(name of individual and title, if any)* _____
was received by me on *(date)* _____.

☐ I personally served the summons on the individual at *(place)* _____
on *(date)* _____; or

☐ I left the summons at the individual's residence or usual place of abode with *(name)* _____
_____, a person of suitable age and discretion who resides there,
on *(date)* _____, and mailed a copy to the individual's last known address; or

☐ I served the summons on *(name of individual)* _____, who is
designated by law to accept service of process on behalf of *(name of organization)* _____
on *(date)* _____; or

☐ I returned the summons unexecuted because _____; or

☐ Other *(specify)*: _____

My fees are \$ _____ for travel and \$ _____ for services, for a total of \$ _____ 0.00.

I declare under penalty of perjury that this information is true.

Date: _____

Server's signature

Printed name and title

Server's address

Additional information regarding attempted service, etc:

UNITED STATES DISTRICT COURT

for the

Eastern District of North Carolina

Richard Fredrick Lanier, et al.

Plaintiff(s)

v.

Syngenta AG, et al.

Defendant(s)

Civil Action No.

SUMMONS IN A CIVIL ACTION

To: *(Defendant's name and address)* Syngenta Seeds
d/b/a Novartis Seeds
11055 Wayzata Boulevard
Minnetonka, MN 55305

A lawsuit has been filed against you.

Within 21 days after service of this summons on you (not counting the day you received it) — or 60 days if you are the United States or a United States agency, or an officer or employee of the United States described in Fed. R. Civ. P. 12 (a)(2) or (3) — you must serve on the plaintiff an answer to the attached complaint or a motion under Rule 12 of the Federal Rules of Civil Procedure. The answer or motion must be served on the plaintiff or plaintiff's attorney, whose name and address are:

Brian L. Kinsley
Crumley Roberts
2400 Freeman Mill Road
Greensboro, NC 27406

If you fail to respond, judgment by default will be entered against you for the relief demanded in the complaint. You also must file your answer or motion with the court.

CLERK OF COURT

Date: _____

Signature of Clerk or Deputy Clerk

Civil Action No. _____

PROOF OF SERVICE

(This section should not be filed with the court unless required by Fed. R. Civ. P. 4 (l))

This summons for *(name of individual and title, if any)* _____
was received by me on *(date)* _____.

☐ I personally served the summons on the individual at *(place)* _____
_____ on *(date)* _____; or

☐ I left the summons at the individual's residence or usual place of abode with *(name)* _____
_____, a person of suitable age and discretion who resides there,
on *(date)* _____, and mailed a copy to the individual's last known address; or

☐ I served the summons on *(name of individual)* _____, who is
designated by law to accept service of process on behalf of *(name of organization)* _____
_____ on *(date)* _____; or

☐ I returned the summons unexecuted because _____; or

☐ Other *(specify)*: _____

My fees are \$ _____ for travel and \$ _____ for services, for a total of \$ _____ 0.00.

I declare under penalty of perjury that this information is true.

Date: _____

Server's signature

Printed name and title

Server's address

Additional information regarding attempted service, etc: